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CHAPTER 1 
 
Introduction 
 
The bed nucleus of the stria terminalis (BNST) is a group of inter-
connected subnuclei that play critical roles in stress-reward interactions.  An 
interesting feature of this brain region is the massive noradrenergic input that it 
receives (Phelix et al., 1992; Egli et al., 2005).  Important roles for norepinephrine 
in this region have been documented in a number of stress and reward related 
behaviors.  This work has been paralleled over the last several years by efforts to 
understand the actions of norepinephrine on neuronal function in the region.  In 
the introduction to this dissertation I will summarize the current state of these 
research areas. 
Norepinephrine (NE) is an often-overlooked neurotransmitter in the field of 
addiction research, yet over the last decade or so it has become clear that it 
plays a critical role in key aspects of addiction-related behavior. Extensive 
evidence supports the role of NE as a mediator of reward in the brain, for a 
review on this topic see Weinshenker and Schroeder (2007). In particular, NE 
appears to play a significant role in stress-induced reinstatement of drug-seeking 
behavior and in negative reinforcement-based behavior. An individual’s risk of 
relapse to drug-seeking remains high even after undergoing addiction treatment 
(Weiss and Koob, 2001) and exposure to stressful stimuli greatly increases an 
individual’s risk of relapse (Brown et al., 1995; Sinha et al., 1999; Sinha et al., 
2011). Recent clinical trials have shown promise for noradrenergic drugs in 
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attenuating stress-induced drug cravings in humans (Jobes et al., 2011; Sinha et 
al., 2011; Fox and Sinha, 2014; Fox et al., 2014). 
A convergence of animal data indicate that the extended amygdala, which 
includes structures such as the bed nucleus of the stria terminalis (BNST), the 
central nucleus of the amygdala (CeA), and the shell of the nucleus accumbens 
(NAc) (Alheid and Heimer, 1988), is critical in stress-induced reinstatement of 
drug-seeking behavior (Briand et al., 2010). Not surprisingly, these structures 
receive some of the densest noradrenergic innervation in the CNS (Brownstein et 
al., 1974; Phelix et al., 1992; Egli et al., 2005).  In particular, the BNST within the 
extended amygdala is a major site of noradrenergic action in stress-induced 
reinstatement (Aston-Jones et al., 1999; Shaham et al., 2000; Wang et al., 2001; 
Leri et al., 2002; Olson et al., 2006). Additionally, there is evidence to suggest 
that several different types of adrenoreceptors are expressed in the BNST 
(Rainbow et al., 1984; Scheinin et al., 1994; Day et al., 1997; Shields et al., 
2009). Therefore, a better understanding of how NE modulates circuit activity in 
the extended amygdala may provide insight into the underlying mechanisms of 
stress-induced relapse of drug- and alcohol-seeking behavior and lead to the 
identification of new therapies.  
This introduction will focus on the mechanisms by which NE regulates 
signaling within the extended amygdala circuitry, highlighting in particular 
potential actions that may be of relevance to the addiction field. 
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The BNST as a nexus for stress-reward interactions 
The intrinsic and extrinsic circuitry of the BNST has been extensively 
studied and is very complex. This dissertation will focus on some of the known 
extrinsic circuitry of the BNST that is thought to participate in stress and reward 
behaviors. The complete intrinsic and extrinsic circuitry, however, is beyond the 
scope of this introduction and the reader is referred to Dong et al. (2001a, 2001b) 
and Dong and Swanson (2006) for more detailed anatomical discussions. 
Current models propose that the BNST is a part of a neuroendocrine 
striatal-loop (Dong et al., 2001) integrating descending glutamatergic input from 
prefrontal cortical regions, insular cortex, basolateral amygdala (BLA) and other 
brain regions with ascending modulatory inputs, such as the parabrachial 
nucleus (PBN) and then projecting to key midbrain and brainstem homeostatic 
centers (Weller and Smith, 1982; Shimada et al., 1985; Hurley et al., 1991; 
McDonald et al., 1999; Chiba et al., 2001; Dong et al., 2001; Shin et al., 2008).  
For example, the BNST has an inhibitory projection to the paraventricular 
nucleus (PVN) of the hypothalamus (Cullinan et al., 1993; Herman et al., 1994; 
Shammah-Lagnado et al., 2000; Choi et al., 2007) that influences the release of 
ACTH (Herman et al., 1994), which in turn leads to the activation of the 
hypothalamic stress response (Harris, 1948; Herman et al., 2003).  The BNST 
also projects to the nucleus accumbens (NAc) (Dong et al., 2001) and has 
excitatory and inhibitory projections to the ventral tegmental area (VTA) (Georges 
and Aston-Jones, 2001, 2002; Dumont and Williams, 2004; Kudo et al., 2012; 
Jennings et al., 2013; Kudo et al., 2014). Each of these regions has been 
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implicated in reinstatement/relapse related behaviors.  Thus, it is not surprising 
that the extended amygdala plays a key role in the integration of stress and 
reward. A basic, illustrated diagram of this circuitry is shown in Figure 1.  
 
         
 
Figure 1. Illustrated diagram of basic extrinsic BNST circuitry. General 
schematic of the BNST surrounding the anterior commissure, illustrating top-
down excitatory input from regions such as the medial prefrontal cortex (mPFC), 
insular (Ins), hippocampus and basolateral amygdala (BLA). The region 
integrates this input with ascending inputs from a variety of sources, including the 
noradrenergic (NE) input from through the ventral noradrenergic bundle (VNAB). 
 	  
Norepinephrine 
The BNST receives very dense noradrenergic innervation through the 
ventral noradrenergic bundle (VNAB) from the A1 and A2 cell groups in the 
nucleus of the solitary tract (NTS) (Ricardo and Koh, 1978; Woulfe et al., 1988; 
Forray and Gysling, 2004; Banihashemi and Rinaman, 2006). The ventral BNST 
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(vBNST) and the dorsal BNST (dBNST) both receive noradrenergic input 
(Brownstein et al., 1974; Phelix et al., 1992; Egli et al., 2005). Using 
microdialysis, extracellular NE has been shown to be elevated in the extended 
amygdala during both stress and withdrawal (Pacak et al., 1995; Delfs et al., 
2000; Cecchi et al., 2002b; Cecchi et al., 2002a). More recently, fast-scan cyclic 
voltammetry approaches have demonstrated that VNAB stimulation produces 
elevation of NE in both vBNST and dorsomedial BNST (Park et al., 2009), and 
that NE levels rapidly rise and fall in the region in response to an aversive tastant  
(Park et al., 2012). 
 
The Role of Norepinephrine in the Extended Amygdala in Stress-Induced 
Reinstatement 	  
NE plays a key role in reinstatement of reward seeking (Pacak et al., 
1995; Cecchi et al., 2002b; Cecchi et al., 2002a; Ma and Morilak, 2005). 
Intracerebroventricular (ICV) injection of NE reinstates cocaine-seeking behavior  
(Brown et al., 2011), and neurons in the BNST and noradrenergic inputs to the 
BNST are show increased activity during withdrawal from drugs of abuse (Aston-
Jones et al., 1999; Delfs et al., 2000), leading to increased levels of NE (Aston-
Jones et al., 1999; Delfs et al., 2000; Fuentealba et al., 2000).  
The release of NE during times of stress and withdrawal has been shown 
to impact behavior. Note here that withdrawal refers to the prolonged cessation 
of chronic drug/alcohol exposure, often accompanied by heightened anxiety 
responses and other physiologic responses that could drive subsequent 
negative-reinforcement-based behavior.  Rodent behavioral models implicate NE 
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signaling in the aversive symptoms of withdrawal, as measured by conditioned 
place aversion and quantification of physiological somatic signs of withdrawal 
(Aston-Jones et al., 1999; Delfs et al., 2000; Shaham et al., 2000; Wang et al., 
2001), as well as in behavioral responses to stressors (Cecchi et al., 2002b; 
Cecchi et al., 2002a).  Mice lacking dopamine-β-hydroxylase (DBH), an enzyme 
required for NE synthesis, do not demonstrate morphine-induced conditioned 
place preference (CPP) (Olson et al., 2006). Viral restoration of DBH to the NTS, 
but not the locus coeruleus (LC), rescues the morphine-induced CPP behavior 
(Olson et al., 2006). Lesioning of the VNAB blocks stress-induced reinstatement 
of morphine-seeking (Wang et al., 2001). These studies show an important role 
for NE from the NTS in stress-induced reinstatement. Subsequent work has 
focused on the role of particular noradrenergic receptors in stress-induced 
reinstatement. 
 
Multiple Noradrenergic Receptors Modulate Neuronal Signaling 
There are nine different adrenergic receptors (ARs) (Bylund et al., 1994) 
divided into three major classes: α1-, α2-, and β-ARs (Bylund et al., 1994). Each 
type of receptor has three subtypes: α1-ARs include α1a, α1b, and α1d; the α2-ARs 
are α2a, α2b, and α2c; and the β-ARs are β1, β2 and β3 (Bylund et al., 1994). ARs 
are G-protein coupled receptors that can modulate synaptic transmission through 
both pre- and post-synaptic mechanisms. α1-ARs are linked to Gq signaling, α2-
ARs are linked to Gi/o signaling, and β-ARs are linked to Gs signaling (Hein, 
2006). Of these adrenergic receptors, immunohistochemical studies have shown 
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widespread expression of α2a-ARs in the BNST (Shields et al., 2009). Other 
labeling studies have shown expression of α1a, α1b, α2c, β1, and β2 –AR in the 
BNST (Rainbow et al., 1984; Scheinin et al., 1994; Day et al., 1997).  
 
α1- and β-AR Antagonists Block Stress-Induced Reinstatement of Drug-
Seeking 	  
β-ARs and α1-ARs play a role in initiating stress-induced reinstatement. 
Administration of β1-AR and β2-AR antagonists peripherally or directly into the 
CeA or BNST blocks stress-induced reinstatement of cocaine-seeking in rodents 
(Leri et al., 2002; Mantsch et al., 2010; Vranjkovic et al., 2012). Treatment with 
either a non-specific β-AR agonist or a selective β2-AR agonist will induce 
reinstatement of drug-seeking (Vranjkovic et al., 2012). Peripheral administration 
of an α1-AR antagonist, prazosin, blocks footshock-induced reinstatement of 
alcohol-seeking (Le et al., 2011).  These data suggest that these two populations 
of receptors, β-ARs and α1-ARs, are the predominant receptor classes 
responsible for initiating NE-induced reinstatement behavior.  
 Interestingly, while α1-ARs in the BNST have been shown to modulate the 
hypothalamic stress response, β-ARs have not (Cecchi et al., 2002b). For 
example, while injection of α1-AR antagonists or β1- and β2-AR antagonists into 
the BNST reduced anxiety after stress (Cecchi et al., 2002b), only the α1-AR 
antagonist reduced plasma ACTH levels following stress (Cecchi et al., 2002b). 
Both α1-AR antagonists and β-AR antagonists are capable of blocking stress-
induced reinstatement of drug seeking, yet only α1-AR antagonists reduce 
plasma ACTH levels. Therefore, α1-AR modulation of the hypothalamic stress 
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response likely does not contribute to the ability of α1-AR antagonists to 
attenuate stress-induced reinstatement.  
 
α2-AR Agonists Block Stress-Induced Reinstatement of Drug-Seeking 
α2-ARs are commonly thought to act as autoreceptors and also to 
heterosynaptically oppose the actions of α1- and β-ARs.  Consistent with this 
idea, activation of α2-ARs has repeatedly been shown to block stress-induced 
reinstatement (Erb et al., 2000; Highfield et al., 2001; Wang et al., 2001; Mantsch 
et al., 2010). Peripheral administration of α2-AR agonists blocks stress-induced 
reinstatement of heroin-seeking (Shaham et al., 2000) and cocaine-seeking (Erb 
et al., 2000; Highfield et al., 2001; Mantsch et al., 2010). Specifically, in the 
extended amygdala, α2-ARs oppose stress-induced reinstatement, as 
administration of α2-AR agonist directly into the BNST blocks footshock-induced 
reinstatement of morphine-seeking (Wang et al., 2001). In addition, the α2A-AR 
agonist guanfacine is shown to reduce withdrawal-induced anxiety, and this 
reduction in anxiety attenuates reinstatement behavior (Buffalari et al., 2012).  
Interestingly, in addition to withdrawal-induced anxiety, α2A-ARs have been linked 
to other anxiety disorders, such as PTSD. For example, mRNA expression levels 
of the α2A-AR gene (Adra2a) were significantly downregulated in the BNST of 
PTSD-like mice (Lebow et al., 2012). Of note, α2-ARs have been implicated in 
stress-induced reinstatement in humans. Patients being treated for drug 
addiction who are given α2-AR agonists have improved relapse outcomes and 
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show decreases in stress-induced drug cravings (Sinha et al., 2007; Sallee and 
Eaton, 2010; Jobes et al., 2011).  
 In total, the data above suggest that β- and α1-ARs are activated in 
response to stressors in the BNST and drive reinstatement behavior, while α2-
ARs can be activated to oppose the effects of α1- and β-AR activation and block 
stress-induced drug seeking behavior.  This suggests that these groups of 
receptors may have opposing roles in activating BNST neurons and/or regulate 
different populations of cells.  In the following sections, I will first review the 
known actions of these receptors in regulating neuronal activity in the BNST and 
then begin to synthesize these actions in a model. I will also identify some of the 
gaps in this model that the work of this dissertation will seek to fill. A summary of 
the effects of pharmacology directed against different classes of adrenergic 
receptors on stress-induced reinstatement behavior in rodent models is 
summarized in Table 1.  
 
 
 
Table 1. Table listing effects of particular adrenergic receptors on rodent  
        models of stress-induced reinstatement of drug-seeking behavior. 
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Noradrenergic Receptors Modulate Excitatory and Inhibitory Transmission 
Evidence suggests that the actions of NE in the extended amygdala 
influence stress-induced reinstatement of drug-seeking behavior; therefore, it is 
important to understand how NE modulates synaptic transmission to elucidate 
underlying mechanisms. There has been substantial evidence to support a 
heterosynaptic role for ARs in modulating glutamatergic transmission (Delaney et 
al., 2007; McElligott and Winder, 2008; Shields et al., 2009; Nobis et al., 2011) 
and inhibitory transmission (Dumont and Williams, 2004; Shields et al., 2009) in 
the extended amygdala. The effect of NE on synaptic transmission in the BNST 
appears to depend on duration of NE application (McElligott and Winder, 2008), 
previous alterations in noradrenergic signaling (McElligott and Winder, 2008; 
McElligott et al., 2010), and type of adrenergic receptor activated (Egli et al., 
2005). Studies have shown α1-ARs and α2-ARs depress excitatory synaptic 
transmission (Dumont and Williams, 2004; Egli et al., 2005; McElligott and 
Winder, 2008; Shields et al., 2009) as well as inhibitory transmission (Shields et 
al., 2009), while β-ARs are capable of enhancing both excitatory transmission 
(Egli et al., 2005; Nobis et al., 2011) and inhibitory transmission (Dumont and 
Williams, 2004). Work has also suggested that α2-ARs are able to differentially 
regulating glutamatergic inputs to the extended amygdala (Delaney et al., 2007).  
ARs are capable of intricate modulation of synaptic transmission in the extended 
amygdala in response to diverse stress and reward stimuli and these 
modulations may underlie stress-induced reinstatement. A graph illustrating 
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potential time-dependent actions of different adrenergic receptor classes is 
shown in Figure 2.  
 
            
 
Figure 2. Schematic of the actions of norepinephrine in the BNST. Graph 
illustrating potential time-dependent overall actions of different NE receptor 
classes on BNST function. Left axis is the relative excitation or inhibition of BNST 
function over time, right axis is extracellular NE levels. 
 
 
β-ARs Enhance Excitatory and Inhibitory Transmission in the BNST 
Both β1- and β2-ARs regulate synaptic transmission and neuronal 
excitability in the BNST.  Administration of the β-AR agonist isoproterenol 
enhances both evoked (Egli et al., 2005) and spontaneous excitatory synaptic 
transmission (Nobis et al., 2011).  Noradrenergic enhancement of field potential 
responses in dBNST, which results from effects on excitatory transmission and/or 
cellular excitability, is preferentially blocked by a β2-AR rather than a β1-AR 
antagonist (Egli et al., 2005).  Isoproterenol effects on spontaneous excitatory 
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postsynaptic currents (sEPSCs), however, are blocked by β1-AR antagonists 
(Nobis et al., 2011).  The actions of isoproterenol on sEPSCs are also blocked by 
a CRFR1 antagonist, and mimicked by CRF and Urocortin (Nobis et al., 2011).  
These data suggest that NE may act in the BNST in part through the recruitment 
of endogenous CRF signaling.  This is particularly interesting given evidence 
indicating a serial NE-CRF control of reinstatement behavior (Brown et al., 2011). 
 
α1-ARs Modulate Excitatory Transmission in a Time-Dependent Manner 
Noradrenergic modulation of synaptic transmission in the extended 
amygdala depends on duration of NE action. With a shorter application of NE, 
only a transient depression or enhancement is seen (Egli et al., 2005; McElligott 
and Winder, 2008).	  Extended application of NE to the BNST produces α1-AR-
dependent long-term depression (LTD) of glutamatergic transmission in the 
BNST (McElligott and Winder, 2008) through a postsynaptic mechanism 
(McElligott and Winder, 2008). This LTD is disrupted in mice with chronic 
alterations in adrenergic signaling, such as α2A-AR-knockout (KO) or NET-KO 
mice (McElligott and Winder, 2008), or mice that have undergone chronic stress 
or chronic ethanol exposure (McElligott et al., 2010). The absence of α1-mediated 
LTD in the context of chronic disruption of noradrenergic signaling suggests that 
α1-ARs may be important for long-term control of excitatory transmission in the 
extended amygdala. Thus, prolonged dysregulation of noradrenergic signaling 
interferes with the α1-ARs’ ability to modulate transmission. Further, evidence 
suggests α1-ARs dominate regulation of synaptic transmission after prolonged 
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exposure to NE by ultimately inducing LTD (McElligott and Winder, 2008), 
regardless of whether the initial response to NE is a β2-AR-mediated increase in 
excitatory transmission or an α2-AR-mediated decrease of excitatory 
transmission (Egli et al., 2005). 
 In addition to transient depression in excitatory signaling, acute actions of 
NE on α1-ARs causes a transient increase of inhibitory transmission through a 
presynaptic mechanism (Dumont and Williams, 2004). Initially, NE signaling 
through α1-ARs may predominantly activate presynaptic α1-ARs that enhance 
inhibitory transmission in the short term. After prolonged stimulation, post-
synaptic α1-ARs may be predominantly activated thus depressing excitatory 
transmission (McElligott and Winder, 2008; McElligott et al., 2010). α1-ARs would 
then have the ability to depress activity in the BNST both short-term, through 
enhancement of GABAA inhibitory postsynaptic currents (IPSCs), as well as long 
term, through long-term depression (LTD). One interesting caveat, however, is 
that, as with the β1-AR actions described above, evidence suggests that transient 
activation of α1-ARs leads to acute enhancement of spontaneous excitatory 
transmission in the BNST through recruitment of CRF signaling (McElligott et al., 
2010).  
The ability of α1-ARs to induce LTD in the extended amygdala suggests a 
possible mechanism for α1-ARs in modulating the hypothalamic stress-response 
after exposure to a prolonged stressor. As previously discussed, α1-ARs in the 
extended amygdala are capable of modulating the stress response, with injection 
of α1-AR antagonists into the BNST decreasing levels of plasma ACTH (Cecchi 
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et al., 2002b). By modulating excitatory or inhibitory transmission in the BNST, 
α1-ARs may affect the strength of the BNST’s inhibitory projection to the PVN, 
therefore influencing the downstream hypothalamic stress response.  
 
α2-ARs Mediate Short-term Depression of Excitatory and Inhibitory 
Transmission 	  
Early studies indicated an important role for α2-ARs in mediating inhibitory 
effects of NE in the BNST (Sawada and Yamamoto, 1981).  Like α1-ARs, α2-ARs 
depress synaptic transmission in the BNST through heterosynaptic mechanisms 
(Delaney et al., 2007; Shields et al., 2009).  As previously, there are three types 
of α2-ARs expressed in the brain: α2A-ARs, α2B-ARs, and α2C-ARs (Bylund et al., 
1994). While expression of α2B-AR mRNA is predominantly limited to the 
thalamus (Scheinin et al., 1994), expression of α2A-AR and α2C-AR mRNA is 
widespread in the brain (Scheinin et al., 1994). Expression patterns of α2A-AR 
mRNA and α2C-AR mRNA are similar and include regions such as the 
amygdaloid complex, the NTS, and the hypothalamus (Scheinin et al., 1994).  
Previous work done by our lab suggests that functionally the α2A-ARs are the 
predominant subtype of α2-ARs to modulate synaptic transmission in the BNST 
(Egli et al., 2005). For example, previous studies from our lab show that the 
effects of the general α2-AR agonist UK-14,314 on excitatory transmission in the 
dorsal BNST are nearly absent in α2A-AR-KO mice, thus indicating that α2A-ARs 
are the primary receptor through which α2-AR agonists depress excitatory 
transmission in the dorsal BNST (Egli et al., 2005). Therefore, since α2A-ARs 
have widespread expression in the dorsal BNST (Scheinin et al., 1994; Shields et 
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al., 2009) and appear to be the primary α2-AR subtypes responsible for 
modulation of synaptic transmission in the dorsal BNST (Egli et al., 2005), this 
dissertation will focus specifically on the actions of α2A-ARs in the BNST. 
 The distribution of α2A-ARs in the BNST suggests a prominent role for 
α2A-ARs in modulating glutamatergic transmission. Immunohistochemical studies 
reveal that α2A-ARs in the BNST are more broadly distributed than noradrenergic 
terminals and instead closely resemble distribution of glutamatergic terminals 
(Shields et al., 2009). Functionally, activation of α2-ARs in the BNST leads to a 
decrease in excitatory transmission (Egli et al., 2005; Shields et al., 2009; 
Krawczyk et al., 2011). Recent studies have shown that application of the 
selective α2A-AR agonist, guanfacine, leads to a decrease in both excitatory and 
inhibitory synaptic transmission in the BNST (Shields et al., 2009). Unlike α1-
ARs, the depression of synaptic transmission by α2-ARs occurs through a 
presynaptic mechanism (Shields et al., 2009; Krawczyk et al., 2011). Also in 
contrast to α1-ARs, α2-ARs may play a greater role in short-term depression of 
synaptic transmission (Egli et al., 2005).  
 
Norepinephrine integration of AR actions 
Prior alterations in noradrenergic signaling can influence which ARs are 
recruited by NE. For example, with brief application of NE, α1-ARs have been 
shown to enhance IPSC frequency in the BNST (Dumont and Williams, 2004). 
However, during acute withdrawal from morphine, NE-treated slices also 
demonstrate increased IPSC frequency but instead through a β-AR-dependent 
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mechanism (Dumont and Williams, 2004). Therefore, although the overall 
outcome of enhanced inhibitory transmission is the same whether through α1- or 
β-ARs, the physiological circumstances under which NE is released in the 
extended amygdala seems to influence which receptors regulate synaptic 
transmission.  
While brief application of NE to a slice might mimic a brief stressor, 
withdrawal may lead to long-term changes in NE signaling that affect the basal 
activity of ARs and thus their likelihood of recruitment by subsequent NE 
signaling. Evidence suggests that the recruitment of β-ARs by NE depends on 
their initial state of activity before NE application (Egli et al., 2005). If enhanced 
excitatory transmission does not occur with initial slice application of NE, 
subsequent treatment with β-AR agonists will not lead to β-AR-mediated 
enhancement of excitatory transmission (Egli et al., 2005). However, if excitatory 
transmission is enhanced by initial NE application, subsequent β-AR agonists will 
cause a similar enhancement of excitatory transmission (Egli et al., 2005). 
Withdrawal may therefore influence the initial state of β-ARs, increasing their 
likelihood of recruitment by NE signaling. In other studies, β-ARs have been 
shown to enhance excitatory synaptic transmission through processes that rely 
on concurrent activation of other receptors, such as α2-ARs (Egli et al., 2005) and 
CRFR1 receptors (Nobis et al., 2011). Therefore, the initial state of the β-ARs 
may also rely on signaling through other receptors. As a result, β-ARs may be 
poised to integrate stress and reward information received from inputs that signal 
through different neurotransmitters, for example integrating NE 
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neurotransmission with CRF neurotransmission. The ability of β-ARs to enhance 
synaptic transmission in the extended amygdala may rely on both prior 
noradrenergic signaling and on activation of other receptors. 
 
α2-ARs Differentially Modulate Individual Inputs to the Extended Amygdala 
α2-ARs appear to differentially regulate synaptic transmission from 
individual inputs to the extended amygdala (Delaney et al., 2007; Savchenko and 
Boughter, 2011; Flavin et al., 2014). As in the BNST, NE signaling in the CeA 
has been shown to heterosynaptically depress glutamatergic transmission 
through α2-ARs (Delaney et al., 2007). Further, NE has differential effects on the 
modulation of the glutamatergic inputs to the CeA from the PBN and the BLA 
(Delaney et al., 2007). One of the goals of the work in this dissertation will be to 
determine is glutamatergic inputs to the BNST are also specifically regulated by 
α2A-ARs.  
The BNST receives many glutamatergic inputs that are involved in 
processing stress stimuli, including the basolateral amygdala (BLA), the insular 
cortex, the infralimbic cortex, the PBN, and the hippocampus (Weller and Smith, 
1982; Shimada et al., 1985; Hurley et al., 1991; McDonald et al., 1999; Chiba et 
al., 2001; Dong et al., 2001; Shin et al., 2008). The PBN is one of the more 
prominent glutamatergic inputs to the BNST and is an ascending input (Shimada 
et al., 1985; Dobolyi et al., 2005) that forms characteristic axosomatic synapses 
onto dorsal BNST neurons (Shimada et al., 1989). The PBN input to the 
extended amygdala has been implicated in a wide range of behaviors including 
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pain sensitization (Han et al., 2005; Han et al., 2010), fear conditioning (Sink et 
al., 2013a), and feeding (Carter et al., 2013).  The PBN has also been implicated 
in behaviors such as taste aversion (Mungarndee et al., 2006) and hypercapnic 
arousal (Kaur et al., 2013). The BLA has been implicated in fear conditioning and 
cue-induced reinstatement of drug-seeking (Rosenkranz et al., 2006; Onur et al., 
2009; Buffalari and See, 2010). It may be interesting to compare what factors 
regulate glutamatergic transmission from each of these inputs to the BNST as it 
may reveal mechanisms underlying stress and relapse behaviors. 
The PBN is a unique input to the BNST in that it forms axosomatic 
synaptic contacts in the BNST, particularly in the dorsal BNST (Shimada et al., 
1989; Dobolyi et al., 2005). These axosomatic contacts formed by the PBN input 
to the dorsal BNST resemble the axosomatic contacts formed by purkinje fibers 
in the cerebellum (Eccles et al., 1966). Further, the PBN input to the BNST 
contains calcitonin gene-related peptide (CGRP), a high-fidelity marker of PBN 
inputs within the BNST (Shimada et al., 1985; Shimada et al., 1989; Dobolyi et 
al., 2005). Projections from the PBN to the BNST are believed to be the only 
source of CGRP within the BNST (Shimada et al., 1985). CGRP 
immunoreactivity from the PBN is densest in the dorsal anterolateral portions of 
the BNST (Dobolyi et al., 2005; Gungor and Pare, 2014). Therefore, we are able 
to use CGRP as a marker of PBN terminals in the BNST, though one cannot 
exclude the possibility that there may be other PBN inputs to the BNST that are 
not CGRP-containing. In the work done in the dissertation, I use CGRP as a 
marker to the PBN input to the BNST. Finally, the PBN has previously been 
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demonstrated to contain vGluT2-containing projection neurons (Niu et al., 2010; 
Kaur et al., 2013). Therefore, I am able to target the PBN projection to the BNST 
with channelrhodopsin (ChR2) by expressing ChR2 under a CaMKIIα promoter 
that directs ChR2 expression to glutamate neurons of the PBN. 
 Previous studies using electrical stimulation to isolate glutamatergic 
inputs suggest that α2-ARs may differentially modulate the PBN and the BLA 
inputs to the CeA (Delaney et al., 2007). Therefore, we hypothesize that the PBN 
and BLA inputs to the BNST are specifically modulated by α2A-ARs and we will 
investigate this hypothesis in Chapter 1 of this dissertation. Differential 
modulation could have important implications for understanding the circuitry 
underlying the relationship between stress and reward-seeking, as specific 
glutamatergic inputs could have a stronger influence on synaptic transmission in 
the extended amygdala, contingent on activation of α2-ARs.  
Further evidence of differential regulation of glutamatergic inputs to the 
extended amygdala through α2-ARs has been shown by increased c-fos 
expression, indicating activation of BNST and CeA neurons, after treatment with 
an α2A-AR agonist (Savchenko and Boughter, 2011). The c-fos expression 
following treatment with an α2A-AR agonist could indicate α2A-AR-mediated 
enhancement of excitatory synaptic transmission for some inputs to the CeA and 
BNST, which would contrast with previous work showing α2A-ARs depress 
excitatory transmission (Egli et al., 2005; Shields et al., 2009; Flavin et al., 2014).  
Alternatively, these fos data may reflect direct α2A-AR actions on a subpopulation 
of BNST neurons or on inhibitory transmission onto those neurons. We will 
	   20 
further investigate this population of c-fos expressing neurons in Chapter 2 of this 
dissertation. 
 
Summary 
Evidence implicates ARs in the extended amygdala in stress-induced 
reinstatement of drug-seeking behavior. In the BNST, β- and α2-ARs may be 
critical in integrating information from different inputs to the extended amygdala. 
β-ARs may integrate signals from different neurotransmitters, such as α2-ARs 
(Egli et al., 2005) and CRFR1 (Nobis et al., 2011). Activation of these receptors 
may help to determine the initial state of β-AR responsiveness to NE, thus 
determining subsequent response to β-AR agonists (Egli et al., 2005).  
 α2-ARs play a role in transient depression of excitatory transmission and 
may differentially modulate excitatory inputs to the extended amygdala. 
Differential modulation would allow for certain inputs to dominate regulation of 
synaptic transmission in the extended amygdala depending on the neural context 
of information reaching the BNST. Integration of inputs to the extended amygdala 
and modulation of neural activity within the region allow ARs to regulate stress-
induced reinstatement of drug-seeking. 
While some of the key ARs underlying stress-induced relapse of drug-
seeking behavior have been identified, there is still work to be done in 
understanding the specific mechanisms of stress-induced relapse. In particular, 
there is a need for an understanding of the particular afferent and efferent 
connections of the BNST that may be modulated by specific ARs. Delaney et al., 
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2007 have shown that the PBN and BLA inputs to the CeA appear to be 
differentially modulated by α2-ARs. It is quite possible that many of the extended 
amygdala’s inputs and outputs are differentially modulated by ARs. An 
understanding of such differential modulation would further elucidate the specific 
neural circuitry underlying stress-induced relapse.  
Additionally, the BNST is composed of a heterogenous population of cells, 
including interneurons and projection neurons. Various types of ARs may 
differentially modulate excitability of these various cell types within the BNST. 
Both differential modulation of afferents to the BNST and differential changes in 
excitability of various cell types within the BNST may influence the excitability of 
the BNST’s projections neurons. A deeper understanding of how various ARs 
modulate the strength of the BNST’s downstream projections would elucidate 
some of the key components of the neural circuitry that are engaged during 
stress-induced reinstatement of drug-seeking. Thus, investigation of how ARs 
regulate synaptic transmission in the extended amygdala may also shed light on 
the therapeutic potential for α1- and β-antagonists and α2-agonists in preventing 
stress-induced relapse of drug-seeking.  
The relatively recent emergence of both in vivo and ex vivo optogenetic 
approaches will be a very powerful tool in dissecting the neural circuitry 
underlying stress induced reinstatement and in dissecting the regulation of this 
circuitry by ARs. In this dissertation, we will use ex vivo optogenetic approaches 
to investigate the specific regulation of glutamatergic transmission from the PBN 
and the BLA to the BNST in hopes of better understanding some of the neural 
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circuitry that allows α2-AR agonists to block stress-induced reinstatement of drug-
seeking in mice. We will also investigate a population of neurons in the BNST 
that expresses c-fos in response to in vivo guanfacine treatment in an effort to 
understand if α2A-ARs have more than one effect on synaptic transmission and/or 
neuronal activation in the BNST.  
Overall, the work in this dissertation will address:  
 
Hypothesis: α2A-receptors differentially regulate glutamatergic 
transmission in the BNST. 
 
Aim 1: Test the hypothesis that the inputs from the BLA, the insular cortex, 
and the parabrachial nucleus to the BNST are differentially regulated by 
α2A-ARs.   
 
Aim 2: Test the hypothesis that a population of BNST neurons is activated 
by α2A-ARs, and explore the properties of this neuronal population.  
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CHAPTER II 
 
α2A-Adrenergic Receptors Filter Parabrachial Inputs to the Bed Nucleus of 
the Stria Terminalis 
 
 
α2-adrenergic receptors (AR) within the bed nucleus of the stria terminalis 
(BNST) reduce stress and reward interactions in rodent models. In addition to 
their roles as autoreceptors, BNST α2A-ARs suppress glutamatergic 
transmission.  One prominent glutamatergic input to the BNST originates from 
the parabrachial nucleus (PBN) and consists of asymmetric axosomatic 
synapses containing CGRP and vGluT2. Here we provide immunoelectron 
microscopic data showing that many asymmetric axosomatic synapses in the 
BNST contain α2A-ARs. Further, I examined optically-evoked glutamate release 
ex vivo in BNST from mice with virally-delivered channelrhodopsin2 (ChR2) 
expression in PBN.  In BNST from these animals, ChR2 partially colocalized with 
CGRP, and activation generated excitatory postsynaptic currents (EPSCs) in 
dorsal anterolateral BNST neurons that elicited two cell-type specific outcomes; 
1) feed-forward inhibition or 2) an EPSP that elicited firing.  I found that the α2A-
AR agonist guanfacine selectively inhibited this PBN input to the BNST; 
preferentially reducing the excitatory response in ex vivo mouse brain slices. To 
begin to assess the overall impact of α2A-AR control of this PBN input on BNST 
excitatory transmission, I used a Thy1-COP4 mouse line with little postsynaptic 
ChR2 expression nor colocalization of ChR2 with CGRP in the BNST.  In slices 
from these mice, I found that guanfacine enhanced, rather than suppressed, 
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optogenetically-initiated excitatory drive in BNST.  Thus, our study reveals 
distinct actions of PBN afferents within the BNST and suggests that α2A-AR 
agonists may filter excitatory transmission in the BNST by inhibiting a component 
of the PBN input while enhancing the actions of other inputs. 
 
Introduction 
Risk of relapse to drug-seeking behavior in addicts remains high even after 
treatment (Weiss and Koob, 2001) and stress increases relapse risk (Brown et 
al., 1995; Sinha et al., 1999; Sinha et al., 2011). In recent studies, α2-AR agonists 
have shown promise in curbing cravings in drug-addicted individuals (Sinha et 
al., 2007; Jobes et al., 2011; Fox and Sinha, 2014; Fox et al., 2014). These 
clinical data are supported by rodent data demonstrating that α2-AR agonists 
reduce stress-induced reinstatement of drug-seeking behavior in rats (Erb et al., 
2000; Shaham et al., 2000; Highfield et al., 2001; Mantsch et al., 2010).  
Noradrenergic signaling in the bed nucleus of the stria terminalis (BNST) 
plays an important role in stress-induced relapse to drug-seeking behavior  
(Aston-Jones et al., 1999; Erb et al., 2001; Briand et al., 2010; Flavin and 
Winder, 2013). Direct administration of α2-AR agonists into the BNST reduces 
stress-induced reinstatement of drug-seeking behavior (Wang et al., 2001), as 
well as conditioned place aversion from morphine withdrawal (Delfs et al., 2000). 
α2A-ARs are widely expressed in the BNST (Shields et al., 2009). In addition to 
their autoreceptor function, α2A-ARs in the BNST can heterosynaptically 
modulate excitatory transmission (Shields et al., 2009; Krawczyk et al., 2011). 
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The BNST receives many glutamatergic inputs from which α2A-ARs may 
modulate excitatory transmission. A better understanding of which excitatory 
inputs to the BNST are selectively modulated by α2A-ARs may help elucidate 
neural circuitry underlying the ability of α2-ARs agonists to block stress-induced 
reinstatement of drug-seeking in rodent models. 
One of the more prominent glutamatergic inputs to the BNST is an ascending 
input from the parabrachial nucleus (PBN) (Shimada et al., 1985; Shimada et al., 
1989; Dobolyi et al., 2005) that forms axosomatic synapses onto dorsal BNST 
neurons (Shimada et al., 1989; Dobolyi et al., 2005). These axosomatic inputs 
contain both the neuropeptide CGRP as well as vGluT2 (Shimada et al., 1985; 
Shimada et al., 1989; Dobolyi et al., 2005; Niu et al., 2010; Kaur et al., 2013). 
The PBN input to the extended amygdala, which includes both the BNST and the 
central nucleus of the amygdala (CeA), has been implicated in a wide range of 
behaviors including pain sensitization (Han et al., 2005; Han et al., 2010), taste 
aversion (Mungarndee et al., 2006), fear conditioning (Sink et al., 2013a), 
hypercapnic arousal (Kaur et al., 2013), and feeding (Carter et al., 2013). 
Previous studies using electrical stimulation to target glutamatergic inputs 
suggest that α2-ARs may differentially modulate the PBN and basolateral 
amygdala (BLA) inputs to the CeA (Delaney et al., 2007). 
Here I demonstrate that the α2A-AR agonist guanfacine selectively regulates a 
PBN input to the BNST. I also show that optical PBN afferent stimulation in the 
BNST generates two different responses and that these responses are 
differentially inhibited by guanfacine. Conversely, we show that in a mouse line 
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where ChR2 is widely expressed, but not colocalized with BNST CGRP, α2A-AR 
activation enhances the response to other inputs, suggesting a role in filtering 
information. 
 
Methods 
Microinjection surgeries 
5-10 week old male C57Bl/6J mice (Jackson Laboratory) were used. All 
mice were group-housed and on a 12-h light/dark cycle. Mice were given access 
to food and water ad libitum.  During surgeries, mice were anesthetized with 
isoflurane and injected intracranially with an adeno-associated virus (AAV5) 
encoding channelrhodopsin (ChR2) fused to YFP, under the control of a CaMKIIα 
promoter (AAV-CaMKIIα-ChR2:YFP; University of North Carolina Vector Core). A 
targeted microinjection of the virus (100-150 nl) was made into one of the 
following sites according to the Franklin and Paxinos mouse brain atlas: the BLA 
(AP: -1.58, ML: +/-2.90, DV: -5.11) or the PBN (AP: -5.34, ML: +/-1.26, DV: -
3.64). Mice were treated with 1 mg/kg injections of ketoprofen for 72 hours 
following surgery. Virally injected mice were killed 6 to 12 weeks after surgery for 
anatomical and electrophysiological analysis. 
To confirm specificity of injection into the PBN, 7 male C57Bl/6J mice 
(Jackson Laboratory) 7-10 weeks old were injected with 150 µl of AAV5-
CaMKIIα-ChR2:YFP virus unilaterally into the hindbrain, targeted to the PBN. 
After 6 weeks survival, brains were removed under deep Nembutal anesthesia 
and immersion fixed in 4% paraformaldehyde. Frozen sections were cut on a 
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cryostat and the locations of injection sites were compared to fiber densities in 
the ipsilateral BNST by imaging for ChR2-YFP fluorescence. Few or no fibers 
were seen in the BNST when injection sites were lateral, rostral or caudal to the 
PBN (n=1 each). Injections medial to the PBN were avoided because of the 
known projections of the locus coeruleus to the BNST (Aston-Jones et al., 1999). 
In two mice, virus injections appeared to be confined to the dorsal PBN and only 
a few ChR2-YFP positive fibers were visible in each 40 µm section of the BNST. 
In two other mice, the injection site included both dorsal and ventral parts of the 
PBN and a moderate density of ChR2-YFP fibers was seen in the BNST (Figure 
3 D1). Henceforth, viral injections were targeted to both dorsal and ventral PBN. 
When the viral injection site was confined to the PBN, ChR2-YFP fibers in the 
BNST were tyrosine hydroxylase negative (n=2), suggesting that afferents from 
the locus coeruleus were not part of the ChR2-YFP positive fiber population 
imaged and light activated in this study (data not shown).  
 
Fluorescent Immunohistochemistry 
For immunohistochemical colocalization studies, 6 additional male 
C57Bl/6J mice that had the AAV5-CaMKIIα-ChR2:YFP virus injected into the 
PBN six weeks earlier, and three B6.Cg-Tg(Thy1-COP4/EYFP)9Gfng  (Thy1-
COP4) transgenic mice (Jackson Laboratory, strain ID 007615), were 
transcardially perfused with 10 mL of ice-cold phosphate-buffered saline (PBS), 
followed by 20 mL of ice-cold 4% paraformaldehyde in PBS. Thy1-COP4 
transgenic mice express ChR2-YFP widely in the brain under the direction of the 
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pan-neuronal Thy1 promoter. Multiple founder lines exist with variations in overall 
expression pattern, likely due to differences in copy number and insertion site of 
the transgene (Arenkiel et al., 2007).  Brains were post-fixed in 4% 
paraformaldehyde overnight at 4°C and were then transferred into 30% sucrose 
and stored for 2 to 10 days at 4°C. Coronal sections of were cut on a cryostat 
(Leica, CM3050S) at a thickness of 40 µM. Sections containing the BNST were 
free-floated in PBS for immuno-labeling. Sections were permeabilized for 30 
minutes with 0.5% Triton-X 100 in PBS at room temperature (RT). Next, non-
specific binding was blocked with 10% normal donkey serum in PBS containing 
0.1% Triton-X-100 for one hour at RT. Sections were then incubated in primary 
antibody in PBS containing 0.1% Triton-X-100 for 2 days at 4°C, followed by 4 x 
10 minute PBS washes.  Sections were then incubated overnight at 4°C with 
secondary antibodies in PBS containing 0.1% Triton-X-100. Finally, sections 
were washed with PBS (4 x 10 minutes), mounted on Fisher + slides (Fisher 
Scientific) and coverslipped with PolyAquamount (Polysciences).   
Images of fluorescent marker-labeled brain sections and viral vector 
injection sites were taken with a Zeiss 710 confocal microscope.  Lenses used 
included a 20X/0.80 N.A. Plan-Apochromat and a 63X/1.4 N.A. Plan Apochromat 
oil. Excitation/emission wavelengths (nm) for each fluorophor were; Dylight 405, 
405/410-505; YFP, 512/519-553; cy3, 561/566-600; cy5, 633/638-759. Mosaic 
image stitching was done with Zeiss ZEN software. 
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Image Analysis 
The neuropeptide CGRP is a marker of the PBN input to the BNST 
(Shimada et al., 1985; Shimada et al., 1989; Dobolyi et al., 2005). I sought to 
further illustrate the level of colocalization of CGRP immunofluorescence with 
ChR2-YFP fluorescence in the BNST of both Thy1-COP4 mice and mice that had 
PBN injections of AAV5-CaMKIIα-ChR2:YFP. I did this as a means of assessing 
the relative expression of ChR2 on PBN terminals in the BNST of these two 
types of mice.  I used ImageJ (Fiji) software to visualize the colocalization of 
CGRP immunohistochemistry fluorescence with ChR2-YFP fluorescence in the 
BNST. From each of these types of mice, I selected images (63x) of BNST cells 
that had an observed CGRP-containing axosomatic contact, as CGRP-containing 
axosomatic synapses are found in projections from the PBN to the dorsal BNST 
(Dobolyi et al., 2005). I then drew a line through the selected cell body as well as 
the neuropil immediately surrounding the soma. I next individually plotted the 
Gray Value (y-axis) versus distance (µm) for each of the different fluorescent 
markers (CGRP, ChR2, or NeuN) along the line that we drew through the soma 
and the immediately-surrounding neuropil. Next, I overlaid each of the 
fluorescent profiles using PRISM software to visualize the level of overlap in the 
localization of CGRP, ChR2-YFP or NeuN.   
 
Electron Microscopy 
For immunoelectron microscopy, mice were sacrificed and perfused with 
4% paraformaldehyde, 0.2% glutaraldehyde and 0.2% picric acid in PBS.  We 
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perfused hemagglutinin (HA) α2A-AR knock-in (HA α2A-AR KI) mice that label the 
N-terminus of the α2A-AR with an HA tag. This mouse line was developed by Qin 
Wang. The HA-tag on the α2A-AR allows us to use HA antibodies to more easily 
visualize α2A-AR expression, as α2A-AR antibodies show poor specificity.  
In some cases the mice were pretreated with the α2-AR agonist clonidine 
to induce internalization of the hemagglutinin (HA)-tagged α2A-AR.  Animals were 
given intraperitoneal (i.p.) clonidine (1 mg/kg) 30 minutes prior to sacrifice.  The 
brains were blocked and postfixed in 4% paraformaldehyde for 4 hours. Coronal, 
50 µm thick vibratome sections of the brain were cut and stored frozen at -80oC 
in 15% sucrose until immunohistochemical experiments were performed.  The 
care of the animals and all anesthesia and sacrifice procedures in this study were 
performed according to the National Institutes for Health Guide for the Care and 
Use of Laboratory Animals and were approved by the Institutional Animal Care 
and Use Committee of Emory University.   
Single-label immunoperoxidase labeling was performed using a mouse 
monoclonal antibody against the HA tag at a 1:500 dilution (Covance, clone 
16B12).  The single-label immunoperoxidase labeling was performed as 
described previously (Muly et al., 2003).  Briefly, sections were thawed, 
incubated in blocking serum (3% normal goat serum, 1% bovine serum albumin, 
0.1% glycine, 0.1% lysine in 0.01 M phosphate buffered saline, pH 7.4) for one 
hour and then placed in primary antiserum diluted in blocking serum.  After 36 
hours at 4oC, the sections were rinsed and placed in a 1:200 dilution of 
biotinylated horse anti-mouse IgG (Vector) for one hour at RT.  The sections 
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were then rinsed, placed in avidin-biotinylated peroxidase complex (ABC Elite, 
Vector, Burlingame, CA) for one hour at RT, and then processed to reveal 
peroxidase using 3,3'-diaminobenzidine (DAB) as the chromagen.  Sections were 
then post-fixed in osmium tetroxide, stained en bloc with uranyl acetate, 
dehydrated, and embedded in Durcupan resin (Electron Microscopy Sciences, 
Fort Washington, PA).  Selected regions of the BNST were mounted on blocks, 
and ultrathin sections were collected onto pioloform-coated slot grids and 
counterstained with lead citrate.  Control sections processed as above except for 
the omission of the primary immunoreagent, did not contain DAB label upon 
electron microscopic examination.    
Ultrathin sections were examined with a Zeiss EM10C electron 
microscope and immunoreactive elements were imaged using a Dualvision 
cooled CCD camera (1300 x 1030 pixels) and Digital Micrograph software 
(version 3.7.4, Gatan, Inc., Pleasanton, CA).  Images selected for publication 
were saved in TIFF format and imported into an image processing program 
(Canvas 8; Deneba Software, Miami, FL). The contrast was adjusted, and the 
images were cropped to meet size requirements.    
In considering the results of our immunoelectron microscopic examination 
of α2A-AR there are several caveats.  First, it is possible that the presence of the 
HA tag on the knock-in transgenic mouse resulted in an alteration in the 
subcellular distribution of the receptor.  However, other studies of α2A-AR 
receptor localization have found it is localized in dendritic, axonal and glial 
compartments in the locus coeruleus (Lee et al., 1998), the ventrolateral medulla 
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(Milner et al., 1999) and hippocampus (Milner et al., 1998), so if the presence of 
the HA tag had an effect on localization it appears to have been of a quantitative 
nature, and not such as to qualitatively change the localization pattern.  A second 
issue was our use of clonidine pretreatment.  We found this necessary because 
the HA tag is located on an extracellular portion of the receptor and in untreated 
animals the majority of the label appeared to be extracellular, outlining adjacent 
structures.  It is possible that the clonidine-induced internalization also induced 
transport from axon terminals and dendritic spines to more proximal positions in 
the dendritic and axonal arbors.  In clonidine treated animals, we observed that 
dendritic shafts and preterminal axons were the most commonly labeled 
structures; however, it is possible that spines and axon terminals would have 
been more common without clonidine treatment.   
 
Electrophysiology Recordings in the BNST 	  
Brain slice preparation 
Brain slice preparation methods were used as previously described 
(Grueter and Winder, 2005; Grueter et al., 2006; Shields et al., 2009). Mice were 
removed from colony and allowed to acclimate for one hour in a Med Associates 
sound-attenuating chamber. Following the acclimation, mice were anesthetized 
with isofluorane and then decapitated. Brains were removed quickly and 
transferred to a 1-4°C oxygenated, low sodium sucrose dissecting solution (in 
mM: 194 sucrose, 20 NaCl, 4.4 KCl, 2 CaCl2, MgCl2, 1.2 NaH2PO4, 10 glucose, 
26 NaHCO3). A Leica vibratome was used to prepare coronal brain slices (300 
	   33 
µm) containing the dorsal BNST. Slices were then transferred to either an 
interface chamber for field potential recordings or to a holding chamber for whole 
cell recordings.  Both the interface chamber and the holding chamber contained 
heated, oxygenated artificial cerebral spinal fluid (ACSF) that was composed of 
(in mM): 124 NaCl, 4.4 KCl, 2.5 CaCl2, 1.3 MgSO4, 1 NaH2PO4, 10 glucose, 26 
NaHCO3. 
 
Field potential recordings 
For field potential recordings, Thy1-COP4 transgenic mice of at least 5 
weeks in age were used.  Slice preparation for field potential recordings in the 
dlBNST was performed as previously reported (McElligott and Winder, 2008).  
Picrotoxin (25 µM) was added to all recordings to isolate excitatory transmission. 
For optical field potential recordings, light stimulation was produced from a 
Lamba XL light source (Sutter instruments) and shone through a bandpass filter 
(Semrock, 475 nm wavelength, 20 nm bandwidth). The blue light was guided 
from the light source through a water-shielded cable that was positioned 
approximately 5 cm above the surface of the slice, resulting in full-field 
illumination. The light stimulation produced a shift in potential, the optical field 
potential (oN) that was shown to be NBQX sensitive (decreased 76% from mean, 
n=2), similar to the N2 seen in electrical field potential recordings previously 
described (Weitlauf et al., 2004; Egli et al., 2005; Grueter and Winder, 2005). 
pClamp software (Axon Instruments) controlled light pulse duration and 
frequency. For optical field potential recordings, light stimuli were approximately 
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2 ms in duration and occurred every 20 seconds. All field potential data was 
collected using Clampex 10.2 (Molecular Devices). 
 
Analysis of field potential recordings 
All field potential recordings were analyzed via Clampfit 10.2 (Molecular 
Devices) as previously described (Shields et al., 2009). All field recordings 
contain a 20 min baseline prior to agonist application, with the exception of the 
atipamezole pre-incubated experiments for which atipamezole was present 
during baseline, and all data points are normalized to the baseline 5 minutes 
prior to agonist application. Plotted time courses for field experiments are 
represented as one-minute averages. 
  
Optical whole-cell recordings 
Whole-cell voltage-clamp recordings were performed as previously 
reported (Grueter and Winder, 2005; Grueter et al., 2006; Kash and Winder, 
2006; Silberman and Winder, 2013). Briefly, after brain slice preparation, slices 
recovered for one hour in a submerged holding chamber (25°C) containing 
oxygenated  (95% O2/5% CO2) ACSF. After recovery in the holding chamber, 
slices were transferred to the recording chamber where they were continuously 
perfused with oxygenated and heated (25°C) ACSF at a rate of 2 mL/min. For 
optical whole cell recordings, light stimulation was produced from a Lamba XL 
light source (Sutter instruments) shone through a bandpass filter (Semrock, 475 
nm wavelength, 20 nm bandwidth). The blue light was guided from the light 
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source through the objective lens using a double lamp-housing adapter 
(Olympus), resulting in illumination of the slice. Light stimuli were approximately 2 
ms in duration and occurred every 10-20 seconds. oEPSCs of 100-1000 pA were 
recorded while voltage-clamped at -70 mV in the presence of picrotoxin (25 µM). 
While I did not quantify the levels of viral expression for comparison between the 
BLA and the PBN, I adjusted initial oEPSCs from each of the inputs such that all 
baseline oEPSCs were between 100-650 pA at the beginning of each 
experiment. For large starting oEPSCs, neutral density filters and microscope 
apertures were used to adjust light intensity such that all experiments were 
recorded on baseline oEPSCs within the defined amplitude range. Evoked 
oEPSCs were of a short, invariant latency, consistent with monosynaptic 
excitation. In data analysis, oEPSCs were normalized to the amplitude of the 
baseline oEPSCs recorded. After achieving whole-cell configuration, cells were 
allowed to equilibrate for a minimum of 5 minutes before baseline was started. 
Postsynaptic parameters were monitored continuously throughout the duration of 
the experiments. Data are represented as an average of the peak amplitude of 3 
sweeps. For voltage-clamp recordings, electrodes of 2.5-5.0 MΩ were filled with 
(in mM): 117 Cs gluconate, 20 Hepes, 0.4 EGTA, 5 TEA, 2 MgCl, 4 Na2ATP, 0.3 
NA2GTP (pH 7.2-7.4, osmolarity 290-295). Input resistance, holding current, and 
series resistance are monitored continuously. Experiments with input resistances 
that change by 20% or more are excluded from data analysis. All whole cell data 
were recorded with Clampex version 10.2 and analyzed with pClamp version 
10.2 (Molecular Devices). 
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Whole-cell optical current-clamp oEPSP recordings  
Whole-cell current-clamp recordings were performed as previously 
reported (Grueter and Winder, 2005; Grueter et al., 2006; Kash and Winder, 
2006; Silberman et al., 2013). For current-clamp recordings, electrodes of 2.5-5.0 
MΩ were filled with (in mM): 135 K+-gluconate, 5 NaCl, 10 Hepes, 0.6 EGTA, 4 
Na2GTP (pH 7.2-7.4, osmolarity 290-295). There was no picrotoxin in the ACSF. 
After brain slice preparation, slices recovered for one hour in a submerged 
holding chamber (25°C) containing oxygenated  (95% O2/5% CO2) ACSF. After 
recovery in the holding chamber, slices were transferred to the recording 
chamber where they were continuously perfused with oxygenated, RT (25°C) 
ACSF at a rate of 2 mL/min. For optical whole cell recordings, stimulation was 
produced from a Lamba XL light source shone through a bandpass filter. The 
blue light was guided from the light source through the objective lens using a 
double lamp-housing adapter, resulting in illumination of the slice. Light stimuli 
were approximately 2 ms in duration and occurred every 10 seconds. oEPSPs of 
5-25 mV were recorded. After achieving whole-cell configuration, cells were 
allowed to equilibrate for a minimum of 5 minutes before baseline was started. 
Postsynaptic parameters were monitored continuously throughout the duration of 
the experiments. Data are represented as an average of the peak amplitude of 3 
sweeps.  
To determine type of current clamp response, I first applied light 
stimulation to the slice before injecting any current into the cell to establish if the 
cell was PBN-responsive. Approximately 1 out of 10 cells was either PBN-
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unresponsive or the response generated by the light stimulation was too small to 
be appropriately interpreted and classified. I did not record from cells in which the 
oEPSC recorded with PBN stimulation was less than 100 pA. The membrane 
potentials of the cells that we recorded from in the BNST rested between -70 mV 
and -85 mV prior to any current injection. Once it was determined that a BNST 
cell was PBN-responsive, I injected current into the cell until its membrane 
potential was between -45 mV and -60 mV. Within these membrane potentials, 
the cell would either fire or a feed-forward IPSP would be generated. If the cell 
fired within these membrane potentials, I classified it as a PBN-excited cell, if an 
IPSP was observed, I classified the cell as a PBN-inhibited cell. For cell profile 
recordings, current was injected into cells until their membrane potential was 
between -50 mV and -60 mV. Progressive 10 pA current steps current were then 
delivered to the cell from which we determined input resistance. By visual 
inspection of the responses to hyperpolarizing current injection, I determined 
whether a cell exhibited Ih current. From the responses to depolarizing steps, I 
determined if a cell demonstrated fast- or slow-rise action potentials. Fast-rise 
action potentials had an action potential rise time of approximately 25 ms, while 
slow-rise action potentials had a rise time of about 40 ms.  
For drug application experiments, cell type was determined by injecting 
current until the cell membrane potential rested between -45 to -60 mV and then 
cell type was determined by visual inspection as described above. For PBN-
inhibited cells, current was injected into the cell so that the IPSP was observed 
during drug-application recordings. A five-minute baseline of the IPSP was taken 
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before drug application. For PBN-excited cells, no current was injected into the 
cell. A five-minute baseline of the EPSP observed at the resting membrane 
potential of the cell was taken before drug application. 
All whole cell data were recorded with Clampex version 10.2 and analyzed 
with pClamp version 10.2 (Molecular Devices). Recordings contained a 5 to 10 
minute baseline recording prior to drug application. All data points were 
normalized to the first 5 minutes of baseline. Plotted time courses for whole-cell 
experiments are represented as 30 second averages.  
 
Statistics 
Experiments comparing a difference to baseline were analyzed using a 
student’s T-test. Experiments comparing baseline to two consecutive drug 
treatments were compared using a repeated measures one-way ANOVA and a 
Tukey’s multiple comparisons test for pairwise comparisons of baseline versus 
guanfacine-treated, baseline versus atipamezole-treated, and guanfacine-treated 
versus atipamezole-treated. The significance of the presence of Ih currents in 
PBN-inhibited and PBN-excited cells were determined used a Chi Square test. 
Chi Square analysis was also used to determine if the frequency of α2A-AR-
containing asymmetric axosomatic contacts were greater than those for 
symmetric axosomatic or asymmetric axodendritic contacts in both the dorsal 
and the ventral BNST. Results are reported in text and figure legends. Significant 
differences were defined as having a P<0.05. 
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Reagents used 
Guanfacine hydrochloride (Tocris) stock solution was made in water. 
Picrotoxin (Tocris) stock solution was made in DMSO. Atipamezole hydrochloride 
(Tocris) stock solution was made in water. Kynurenic acid (Tocris) was added 
directly to the ACSF. Primary antibodies included mouse monoclonal NeuN 
(Chemicon MAB377; 1:1K), mouse monoclonal anti-GAD67 (Millipore MAB5406; 
1:800) and goat polyclonal anti-CGRP (Abcam ab36001; 1:1K). Secondary 
antibodies labeled with Dylight 405 (715-475-150; 1:250) (for NeuN images), cy3 
for GAD 67 (715-166-150; 1:1K, or cy5 (715-176-150; 1:1K) (for CGRP images) 
and raised in donkeys were purchased from JacksonImmuno Research. For 
immoelectron microscopy, the primary antibody mouse monoclonal anti-HA was 
used (Covance, clone 16B12; 1:500). The secondary antibody used was 
biotinylated horse anti-mouse IgG (Vector BA2000; 1:200). 
 
Results 	  	  
PBN input to the dorsal anterior BNST elicits EPSCs that drive two classes of 
postsynaptic responses 	  
 I used an optogenetic strategy to activate PBN or BLA inputs to the BNST 
through stereotaxic injection of one of these regions with AAV5-CaMKIIα-
ChR2:YFP (Figure 3A, D2, Figure 5F (inset, right)).  After a minimum of 5 weeks, 
mice expressed ChR2-YFP at the injection site (Figure 3 D2, Figure 5F (inset, 
right)), as well as in axons within the BNST (Figure 3 D1 and Figure 5F (inset, 
left)).  
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Figure 3. Optogenetic targeting of the parabrachial input to the BNST.   
A) Illustrated mouse indicating that the experiments done in panels A-E of Figure 
1 used a C57Bl/6J mouse that was injected with AAV5-CaMKIIα-ChR2:YFP at 
least 5 weeks prior. B) Atlas image of BNST slice indicating that we are recording 
within the dorsal BNST while optically stimulating PBN terminals in the BNST 
(Slice image adapted from the Franklin and Paxinos Mouse Brain Atlas). C) 
Representative image of ImageJ (Fiji) image analysis done of a BNST cell and its 
surrounding neuropil after injection of AAV5-CaMKIIα-ChR2:YFP into the PBN of 
a C57/Bl6J mouse 5 weeks prior. Colocalization of the gray value of CGRP 
(purple) with the gray value of ChR2 (green) is observed. D) Image (63x) 
characterizing expression of ChR2-YFP in the BNST (D1, left) and at the PBN 
injection site (D2, right) 5 weeks after microinjection into the PBN. Left shows 
colocalization (yellow, indicated by white arrow) of CGRP (purple) with ChR2-
YFP (green) in the dorsal BNST (D1). Right shows ChR2-YFP expression 
(green) at the PBN injection site (D2). E) Representative traces of the dual 
component oEPSC generated by stimulation of the PBN input to the BNST. F) 
CGRP staining (green) can be seen in the dorsal anterolateral BNST of wild-type 
mice (F1, left) and is absent in CGRP KO mice (F2, right). GAD67 staining is 
shown in the dorsal BNST (red). G) Colocalization of VGluT2 (green) with CGRP 
staining (red) in the dorsal anterolateral BNST. 
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In addition to visual inspection of the injection site, the specificity of the 
ChR2-YFP viral vector injection into the PBN was confirmed by fluorescent 
immunohistochemical colocalization of ChR2-YFP with calcitonin gene-related 
peptide (CGRP), a high-fidelity marker of PBN inputs within the BNST (Shimada 
et al., 1985; Shimada et al., 1989; Dobolyi et al., 2005). Axosomatic synapses 
containing CGRP are found in PBN projections to the dorsal BNST (Shimada et 
al., 1989; Dobolyi et al., 2005).  CGRP-expressing neurons that project from the 
lateral PBN to the extended amygdala have been shown to have functional 
importance. For example, CGRP-containing neurons that project from the outer 
external lateral PBN to the central nucleus have been shown to modulate feeding 
behavior (Carter et al., 2013). Projections from the PBN to the BNST are also 
believed to be the only source of CGRP within the BNST (Shimada et al., 1985). 
Therefore, we used CGRP as a marker of PBN terminals in the BNST, though I 
cannot exclude the possibility that there may be other PBN inputs to the BNST 
that are not CGRP-containing. Colocalization of ChR2-YFP and anti-CGRP 
fluorescent label was seen in the dorsal BNST (Figure 3 D1), indicating that the 
PBN viral injections resulted in expression of ChR2-YFP in PBN axons in the 
dBNST. I also performed image analysis with ImageJ (Fiji) software to illustrate a 
colocalization of ChR2-YFP and CGRP in the BNST, further affirming that some 
CGRP-expressing PBN terminals in the BNST also express ChR2 (Figure 3C). 
Additionally, as has previously been reported, CGRP immunoreactivity was 
densest in the dorsal anterolateral portions of the BNST (Figure 3 F1) (Dobolyi et 
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al., 2005; Gungor and Pare, 2014).  CGRP immunoreactivity was not observed in 
brains taken from CGRPα knockout mouse brains (Figure 3 F2).  
 The PBN has previously been demonstrated to contain vGluT2-containing 
projection neurons (Niu et al., 2010; Kaur et al., 2013). We confirmed that CGRP 
immunoreactivity colocalized with vGluT2 in mouse BNST (Figure 3G).  Further, 
the pattern of ChR2-YFP that we observed in the BNST was overall similar to 
published CGRP immunoreactivity in the BNST (Dobolyi et al., 2005; Gungor and 
Pare, 2014). Therefore, I focused our recordings on the anterior dorsal lateral 
portions of the BNST. Using whole-cell patch clamp recordings from dorsal 
anterolateral BNST neurons in acutely prepared brain slices, I confirmed that 
optical recruitment of these fibers in the BNST using full-field blue LED 
illumination produced excitatory postsynaptic currents (optical EPSCs or 
oEPSCs).  oEPSCs in BNST recorded from PBN-injected mice were observed in 
the vast majority of cells tested.  I could see large oEPSCs ranging up to ~1 nA 
produced by full field illumination.  oEPSC sizes were reduced for study through 
the use of neutral density filters and manipulation of the aperture to produce 
amplitudes for analysis between 100-650 pA therefore keeping all baseline 
oEPSCs within a defined amplitude range. I then stimulated the slice once every 
10-20 seconds. One oEPSC was generated from each light stimulation. Evoked 
oEPSCs were of a very short, relatively invariant latency, consistent with 
monosynaptic excitation. Representative traces of the dual component oEPSC 
generated by stimulation of the PBN input to the BNST are shown in Figure 3E. 
The reversal potential of the synaptic inputs of the PBN onto BNST neurons was 
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-2.7 mV. The AMPA/NMDA ratio of the PBN inputs to the BNST was 0.849 ± 
0.122 (n=5). Application of the AMPA receptor antagonist NBQX (10 µM) 
reduced the oEPSC at -70 mV (80.6% ± 6.1%, t(2)=13.1, p<0.01, n=3). 
Altogether, these data are consistent with full field illumination producing EPSCs 
from activation of the PBN projection to the BNST. 
To establish the impact of the PBN input on BNST neuronal activity, I 
optically stimulated this input while recording in current clamp mode. When 
activating PBN inputs to the BNST in ex vivo slices prepared from C57Bl/6J 
mice that had been injected with AAV5-CaMKIIα-ChR2:YFP at least 5 weeks 
prior (Figure 4A), I observed two overall types of responses to optical stimulation 
of the PBN input to the BNST. Some PBN afferents within the BNST end in large 
axosomatic terminal zones that envelop BNST neurons in a manner consistent 
with “detonator” type synapses such as the climbing fiber input onto Purkinje 
neurons in cerebellum (Eccles et al., 1966; Shimada et al., 1989; Dobolyi et al., 
2005).  Thus, I predicted that I would observe PBN-induced firing in BNST 
neurons.  In 18 of 34 neurons (52.7%) recorded from 14 mice, I indeed observed 
an EPSP followed by burst firing  (Figure 4 B1, B3). In the remaining 16 neurons 
(41.7%), I observed a large inhibitory postsynaptic potential (IPSP) in response 
to PBN stimulation (Figure 4 B2, B3). I hypothesized that this IPSP was 
generated by feed-forward recruitment of either GABA interneurons or GABA 
projection neurons in the BNST, as recent evidence indicates a considerable 
amount of intra-BNST signaling (Poulin et al., 2009; Gungor and Pare, 2014).  
This was confirmed by blocking the IPSP through application of the ionotropic 
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glutamate receptor antagonist kynurenic acid (4 mM, Figure 4 D1, D2, Figure 
4E) (89.9% ± 9.0%, t(4)=10.0, p<0.01, n=5).  
Since the BNST contains many distinct cell types, and I observed that two 
types of responses were exhibited by BNST neurons in response to stimulation 
of the PBN input, I examined the intrinsic excitable properties of these cells to 
determine if the two types of responses were indicative of two populations of 
postsynaptic neurons. I injected hyperpolarizing and depolarizing current in a 
step-wise fashion through the patch clamp electrode into both PBN-inhibited cells 
and PBN-excited cells in the BNST. I noted several features of the cells’ 
responses to current injection that suggested commonality within these two 
response groups and distinctions across the groups (Figure 4 C1, C2, C3).  First, 
I saw that 56% (n=9 out of 16) of PBN-excited cells exhibited Ih current activity 
during hyperpolarizing steps, while only 20% (n=3 out of 15) of PBN-inhibited 
cells exhibited Ih current (Figure 4 C1 compared to Figure 4 C2). Chi squared 
analysis of the presence of Ih current in each of the cell types revealed a 
significant difference between the PBN-inhibited and PBN-excited cells (Chi-
square=4.3, df=1, p<0.05, n=31). Second, PBN-excited cells had significant 
differences in their input resistances from PBN-inhibited cells, with the PBN-
inhibited cells showing lower input resistances  (371.0 MΩ ± 27.3 MΩ, t(23)=3.1, 
p<0.05, n=13) as compared to higher input resistances in PBN-excited cells 
(494.1 MΩ ± 29.1 MΩ, n=12). 
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Figure 4. Parabrachial inputs to the BNST innervate at least two 
types of neurons. A) Illustrated mouse indicating that the experiments done in 
Figure 2 used C57Bl/6J mice that were injected with AAV5-CaMKIIα-ChR2:YFP 
at least 5 weeks prior. B) A representative trace of a PBN-activated cell firing 
action potentials is shown (B1). A representative trace of an IPSP recorded from 
a PBN-inhibited cell is shown (B2). A pie chart showing the relative prevalence of 
each cell type is shown. PBN-activated cells comprise 52.9% of the 34 cells 
recorded from and PBN-inhibited cells comprise 47.1% (B3). C) Step-wise 
current injection into a PBN-activated cell, Ih current can be seen at 
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hyperpolarized potentials (C1). Step-wise current injection into a PBN-inhibited 
cell, no Ih current is seen at hyperpolarized potentials (C2). Overlapping action 
potentials showing that action potentials generated in PBN-activated cells (top) 
have a faster rise time than PBN-inhibited cells (bottom) (C3). D) Kynurenic acid 
(4mM) blocks the feed-forward IPSP generated by PBN-inhibited cells. 
Representative traces of an IPSP prior to drug application (D1) and after drug 
application (D2) are shown. E) Time course showing the block of feed-forward 
IPSPs generated in PBN-inhibited cells by kynurenic acid (4mM), (p<0.01, n=5). 
 
Third, I observed that PBN-inhibited cells had a slower rising phase on their 
action potentials (APs) based on visual inspection, with 15 out of 16 PBN-
inhibited cells showing slower rising APs, compared to PBN-excited cells where 
only 1 out of 15 firing-type cells had slower rising APs (Figure 4 C3, slow-rise 
(bottom trace) compared to fast-rise (top trace)). These differences between 
PBN-inhibited and PBN-excited cells indicate the possibility of two distinct 
populations of cells. 
 
Ultrastructural analysis reveals widespread expression of α2A-AR within the 
BNST and expression in asymmetric axosomatic synapses 	  
 α2A-AR stimulation results in depression of excitatory drive in the BNST 
(Shields et al., 2009).  Previous studies in the CeA suggest the possibility that α2-
ARs presynaptically regulate PBN input to that region (Delaney et al., 2007).  To 
assess the localization of α2A-ARs in the BNST we used a genetically modified 
mouse in which an HA-tag was knocked-in to the N-terminus of the α2A-AR 
(Figure 5 A1). As antibodies for α2A-ARs have poor specificity, we used this 
knock-in mouse so that we were able to visualize α2A-ARs using HA antibodies. 
Our previous light level localization of the α2A-AR using this knock-in HA-tagged-
α2A-AR mouse line suggest heavy expression of this receptor postsynaptic to 
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noradrenergic terminals, in that immunoreactivity far surpassed the pattern of TH 
staining (Shields et al., 2009).  In order to more directly test the idea that α2A-ARs 
are present on excitatory terminals in the BNST, we used immunoelectron 
microscopy to confirm a structural substrate for presynaptic action.  We used the 
HA-α2A-AR knock-in mice described above and used previously (Shields et al., 
2009) (Figure 5 A1) and labeled BNST sections from these mice with an antibody 
directed against the HA tag.  
Initially we observed strong labeling when sections were examined with 
the light microscope but when examined with the electron microscope we 
observed only a few profiles containing DAB in the neuropil of the BNST.  
Instead, we observed what appeared to be DAB reaction product in the 
extracellular space outlining neuropil elements that themselves contained no 
clear label (Figure 5 A2).  We reasoned that this was because the HA tag was 
attached to the N terminus of the receptor, a region predicted to be on the 
extracellular surface when the receptor is on the plasma membrane.  
Accordingly, we pretreated animals with the α2-AR agonist clonidine prior to 
sacrifice to induce internalization of the receptor (Lu et al., 2009).  We found that 
with clonidine pretreatment, the extracellular label was greatly decreased and 
neuropil elements containing DAB label were more common.  Dendritic shafts 
and preterminal axons appeared most commonly labeled in this clonidine treated 
material, but dendritic spines and axon terminals could also be observed, as well 
as some glial processes (Fig. 5B-E).  In some cases the axon terminals could be 
observed making asymmetric synaptic contacts.   
	   48 
 We were particularly interested in the labeled axon terminals.  In order to 
determine the synaptology of α2A-AR containing axon terminals in the dorsal 
BNST, we examined 235 images taken from the dorsal anterolateral BNST in 
four animals, representing 3,872.5 µm2.  We identified a total of 106 asymmetric 
synapses in this sample, 40 terminated onto dendritic shafts and 66 onto 
dendritic spines.  None of the axon terminals giving rise to asymmetric synapses 
onto dendritic shafts were labeled for α2A-AR; 5% of the terminals synapsing onto 
dendritic spines were labeled for α2A-AR (Figure 5F). 
Another possible target for α2A-AR containing terminals in the BNST are 
cell bodies.  Accordingly, we examined 34 cell bodies in dorsal anterolateral 
BNST.  We identified all axon terminals making synaptic contacts onto these 
soma in the single ultrathin section.  A total of 60 synaptic contacts were 
identified, 32 of which were asymmetric and 28 of which were symmetric.  Of the 
terminals making symmetric contacts onto cell bodies, 7% contained label for 
α2A-AR (Figure 5F).  On the other hand, 25% of the terminals making asymmetric 
synaptic contacts onto cell bodies were labeled for α2A-AR (Figure 5F). We 
hypothesized that these α2A-AR-containing terminals making axosomatic 
asymmetric synapses arose from parabrachial nucleus.  To further evaluate this 
hypothesis we examined the axon terminals in the ventral BNST.  We reasoned 
that if our hypothesis was correct the percentage of labeled axosomatic 
syanpses in the ventral BNST should be lower than in the dorsal BNST in 
keeping with the lighter parabrachial innervation of this region of the BNST.  
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Figure 5.  Immunolabeling for HA-tagged α2A-AR in mouse BNST. A) 
Illustrated mouse indicating that the experiments done in Figure 3 used HA-α2A-
AR-knock in mice (A1). Immunolabeling directed against the HA tag produced 
some patches of intracellular labeling in neuronal elements (arrow); however, the 
bulk of labeling observed appeared to be extracellular (arrowhead), appearing to 
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fill spaces between elements of the neuropil, producing the effect of ‘outlining’ 
them with reaction product (A2). B-E) When animals were treated with clonidine 
before sacrifice the ‘outlining’ was less frequent and instead reaction product was 
observed inside neuronal elements.  Dendrites (B, arrow) and preterminal axons 
(C, arrowheads) were commonly observed.  Labeled dendritic spines (C, arrow) 
and axon terminals (D and E, arrows) were also seen.  The labeled axon 
terminals sometimes made asymmetric synaptic contacts (E).  Scale bar, 500 
nm. F) Bar graph showing relative abundance of α2A-ARs in each synapse type in 
both the dorsal and ventral BNST.  
 
 
 
We examined 195 images taken from the ventral BNST in four animals, 
representing 3,213.4 µm2.  We identified a total of 119 asymmetric synapses in 
this sample, 80 terminated onto dendritic shafts and 39 onto dendritic spines.  Of 
the axon terminals giving rise to asymmetric synapses onto dendritic shafts, 
11.3% were labeled for α2A-AR; 7.7% of the terminals synapsing onto dendritic 
spines were labeled for α2A-AR.  We then examined 43 cell bodies in ventral 
BNST.  We identified all axon terminals making synaptic contacts onto these 
soma in the single ultrathin section.  A total of 58 synaptic contacts were 
identified, 31 of which were asymmetric and 27 of which were symmetric.  Of the 
terminals making symmetric contacts onto cell bodies, 7.4% contained label for 
α2A-AR, while 12.9% of the terminals making asymmetric synaptic contacts onto 
cell bodies were labeled for α2A-AR, roughly half the level seen for dorsal BNST 
(Figure 5F).  This is consistent with our hypothesis that these α2A-AR containing 
axosomatic asymmetric synapses arise from the parabrachial nucleus.   
I performed Chi-square analysis on our EM data for both the dorsal and 
ventral BNST to determine if the frequency of α2A-AR-containing contacts were 
greater in asymmetric axosomatic contacts versus symmetric axosomatic 
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contacts. I also performed a Chi-square analysis to determine if the frequency of 
α2A-AR-containing contacts were greater in asymmetric axosomatic contacts 
versus asymmetric axodendritic contacts. In the dorsal BNST, there was no 
statistical difference in frequency of symmetric axosomatic α2A-AR-containing 
contacts versus asymmetric axosomatic α2A-AR-containing contacts (Chi-
square=3.4, df=1, n.s., n=60). There was, however, a significant difference in the 
frequency of asymmetric axosomatic α2A-AR-containing contacts as compared to 
asymmetric axodendritic α2A-AR-containing α2A-ARs contacts (Chi-square=11.3, 
df=1, p<0.01, n=72). In the ventral BNST there was no significant difference 
between the frequency of asymmetric axosomatic α2A-AR-containing contacts 
compared to either symmetric axosomatic α2A-AR-containing contacts (Chi-
square=0.5, df=1, n.s., n=58) or to axodendritic asymmetric α2A-AR-containing 
contacts (Chi-square=0.06, df=1, n=111). 
 In total, these Chi-square analyses reveal that in the dorsal BNST there is 
a higher frequency of α2A-AR-containing asymmetric axosomatic contacts than 
α2A-AR-containing asymmetric axodendritic contacts. It also reveals that there is 
no significant difference between the α2A-AR content of these types of synapses 
in the ventral BNST. This finding is consistent with what is known of the anatomy 
of the PBN input to the BNST, in which CGRP-containing axosomatic inputs from 
the PBN are predominantly observed in the dorsal BNST (Dobolyi et al., 2005). 
While non-axosomatic PBN inputs are observed in the ventral BNST, the overall 
density of PBN projections to the BNST are higher in the dorsal BNST than in the 
ventral BNST (Shimada et al., 1989; Alden et al., 1994). Therefore, the presence 
	   52 
of α2A-ARs on significantly more asymmetric axosomatic synapses selectively in 
the dorsal BNST is consistent with α2A-AR expression on PBN terminals in this 
region. 
 
Guanfacine suppresses oEPSCs elicited by PBN fiber recruitment in BNST 
Given the likelihood that α2A-ARs are present on PBN terminals in the 
BNST, I next assessed whether the α2A-AR agonist guanfacine differentially 
affected individual inputs to the BNST using optogenetic strategies outlined in 
Figure 3. I tested the sensitivity of two different excitatory inputs to the BNST: the 
BLA and the PBN. I targeted the PBN input to the BNST as described above 
(Figure 3, Figure 6A). Voltage-clamped whole-cell recordings were made in the 
presence of 25 µM picrotoxin to further isolate oEPSCs. Application of 
guanfacine (1 µM) depressed oEPSCs produced by activation of PBN afferents 
within the BNST (Figure 6B,C,D) (t(2,8)=9.4, p<0.01, n=7).  After application of 
the selective α2 antagonist atipamezole (1 µM), the amplitude of oEPSCs 
returned to a level not significantly different from baseline (Figure 6B,C).  I did 
observe some variability across experiments (Figure 6C). In some instances, 
such as the individual experiment (Figure 6B), there was a clear depression of 
excitatory transmission by guanfacine that was reversed by atipamezole. In 
contrast, in other experiments weaker effects of guanfacine on excitatory 
transmission were observed (Figure 6C). Additionally, I performed experiments in 
which I applied guanfacine (1 µM) to oEPSCs recorded from stimulation of the 
PBN afferents in the BNST and then allowed for a long washout of guanfacine 
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Figure 6. Guanfacine depresses excitatory transmission from the 
parabrachial nucleus projection to the BNST. A) Illustrated mouse indicating 
that the experiments done in Figure 4 used C57Bl/6J mice that were injected with 
AAV5-CaMKIIα-ChR2:YFP at least 5 weeks prior.  B) Individual experiment 
showing decrease in excitatory transmission of the PBN input to the BNST by 
guanfacine that is reversed by atipamezole (1 µM). Example traces of each 
phase of drug application are shown (insets). C) Individual experiments showing 
that excitatory transmission is significantly decreased from baseline by 
guanfacine (1 µM) (p<0.01, n=7). Subsequent application of atipamezole 
reverses this depression such that amplitudes of oEPSCS are no longer 
significantly different from baseline (n.s., n=7). D) Guanfacine (1 µM) was applied 
to oEPSCs recorded from stimulation of the PBN afferents in the BNST. 
Guanfacine was allowed to washout for 30 minutes. With prolonged washout the 
depression of the excitatory PBN input to the BNST did not reverse to baseline 
levels (p<0.05, n=3). E) Guanfacine (1 µM) has no apparent effect on excitatory 
transmission from the BLA to the BNST in normal ACSF (white circles) (p<0.01, 
n=5). Pre-incubation of ex vivo BNST slices with atipamezole (1 µM) does not 
alter the effect of guanfacine on excitatory transmission from the BLA to the 
BNST (black circles) (p<0.01, n=4). F) Baclofen (10 µM) depresses excitatory 
transmission from the BLA to the BNST (p<0.01, n=9). Image of the BLA injection 
site 5 weeks after injection of the AAV5-CamKIIα-ChR2:YFP into the BLA (inset, 
right). Expression of ChR2-YFP in the dorsal BNST 5 weeks after injection of the 
viral vector into the BLA (inset, left). 
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without subsequent application of atipamezole to the recordings (Figure 6D).In 
such experiments, after prolonged washout of guanfacine, the size of oEPSC did 
not return to baseline levels (Figure 6D) as was observed in Figure 6B,C (48.3 ± 
11.2%, t(2)=4.3, p<0.05, n=3). Therefore, application of the α2-AR antagonist 
atipamezole appears to be necessary for the reversal of the depression of 
excitatory transmission from the PBN to the BNST by guanfacine. 
I also assessed the effect of guanfacine on oEPSCs produced by 
activation of BLA afferents within the BNST using a similar strategy involving 
injection of the ChR2-expressing viral vector (AAV5-CaMKIIα-ChR2:YFP) into the 
BLA 5-12 weeks prior to brain slice preparation.  I observed expression of ChR2-
YFP fluorescence at both the BLA injection site (Figure 6F (inset, right)) and in 
axons within the BNST (Figure 6F (inset, left)). Full field illumination produced 
robust oEPSCs that were brought to a range of 100-650 pA through the use of 
neutral density filters and manipulations of the light aperture. The BLA input to 
the BNST, in the presence of picrotoxin, showed very little, if any, sensitivity to 
guanfacine (Figure 6E, open circles) (32.4% ± 6.3%, t(4)=5.2, p<0.01, n=5).  I 
observed marked rundown in the recordings of the BLA input to the BNST, but 
the extent of the rundown was the same when ex vivo BNST slices were pre-
incubated in atipamezole (1 µM) (Figure 6E, closed circles) (42.7% ± 6.2%, 
t(3)=6.8, p<0.01, n=4) or not (Figure 6E, open circles).  Due to the lack of 
difference between recordings done in normal ACSF and recordings done with 
atipamezole pre-incubation I believe that any differences in amplitude between 
oEPSCs recorded at baseline and oEPSCs recorded after guanfacine application 
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were due to rundown of recordings. In the case of these ex vivo optogenetic 
recordings, I refer to “rundown” as a decrease in the size of the oEPSC over the 
duration of the recording that appears to be independent of either a drug effect or 
of cell health. Interestingly, this rundown was observed in the BLA input to the 
BNST but not the PBN inputs. The 1 µM concentration of atipamezole used was 
previously sufficient to reverse the effect of α2A-AR agonist actions on electrically-
evoked EPSCs (Shields et al., 2009).  To ensure that I would be capable of 
observing Gi/o-protein coupled receptor modulation of BLA inputs in the BNST 
even with the rundown of the oEPSC, we examined actions of the GABAB 
agonist baclofen.  The GABAB receptor is virtually ubiquitously expressed on 
glutamatergic terminals in the CNS, where it depresses glutamate release.  
Despite the rundown observed in our BLA-to-BNST recordings, I was able to 
observe robust depression of oEPSCs elicited by BLA fiber activation by baclofen 
(10 µM) (Figure 6F) (69.6% ± 9.7%, t(8)=7.2, p<0.001, n=9).  While the level of 
expression of α2A-ARs on BLA terminals in the BNST is unknown, our 
electrophysiological data suggest that excitatory transmission from the BLA input 
to the BNST is insensitive to activation of α2A-ARs (Figure 6E). These data 
suggest that guanfacine selectively modulates PBN inputs to the BNST. 
 
Guanfacine depresses PBN-induced current clamp responses on BNST neurons 
As described above, I observed two types of membrane potential 
responses of BNST neurons to stimulation of the PBN input: “PBN-excited” and 
“PBN-inhibited.” I sought to determine if there were any differences in the 
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sensitivity of each type of response to guanfacine. I again targeted the PBN 
using the optogenetic strategies described above (Figure 3, Figure 7A). For PBN-
excited responses, I applied 1 µM guanfacine to the optically-evoked EPSPs 
recorded from the BNST neuron at the cell’s resting membrane potential. I 
observed that PBN-excited cells show a marked decrease in EPSP size with 
guanfacine application (Figure 7B) (40.2% ± 6.0%, t(4)=6.7, p<0.01, n=5). 
Further, this decrease in EPSP size with guanfacine was seen in all PBN-excited 
cells that I tested (Figure 7D). In contrast, while the PBN-inhibited cells showed a 
trend for a decrease in size of IPSP with 1 µM guanfacine application (Figure 7C) 
(15.1% ± 7.4%, t(10)=2.0, n.s., n=11), the decrease was not significant. 
Interestingly, I observed that some PBN-inhibited cells show a decrease in IPSP 
size with guanfacine application, while others did not (Figure 7E). Therefore, the 
lack of significance of the decrease in the IPSP may be due to heterogeneity in 
the sensitivity to guanfacine of the PBN input onto each of these PBN-inhibited 
cells. Further, since these IPSPs are feed-forward, the variability of the IPSPs 
response to guanfacine likely depends on the sensitivity of both the glutamatergic 
input and the intervening inhibitory interneuron to α2A-AR activation by 
guanfacine. 
 
 
Differential action of guanfacine on optically-evoked excitatory responses in 
Thy1-COP4 mouse BNST 	  
Analysis of extracellular field potentials can provide a more global analysis 
of the impact of modulatory receptors on circuit activity by allowing us to record 
from populations of neurons in the BNST.  In examining ChR2-YFP expression 
	   57 
 
 
Figure 7. Guanfacine reduces EPSPs of PBN-activated cells in the BNST. A) 
Illustrated mouse indicating that the experiments done in Figure 5 used C57Bl/6J 
mice that were injected with AAV5-CaMKIIα-ChR2:YFP at least 5 weeks prior. B) 
Guanfacine (1 µM) significantly decreases the size of EPSPs recorded from 
PBN-activated cells in the BNST (p<0.05, n=5). C) Guanfacine (1 µM) has 
variable effects on IPSPs recorded from the PBN-inhibited cells in the BNST 
(n.s., p=11). D) Individual experiments showing the effect of guanfacine (1 µM) 
on EPSPs recorded from PBN-activated cells in the BNST. EPSPs are reduced 
by guanfacine across all experiments. E) Individual experiments showing the 
effect of guanfacine (1 µM) on IPSPs recorded from PBN-activated cells in the 
BNST. The effect of guanfacine on IPSPs is more variable with IPSPs being 
reduced in some experiments and unaltered in others. 
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in Thy1-COP4 transgenic mice, we determined that while ChR2-YFP was heavily 
expressed in regions that project to the BNST such as the BLA, cortical regions, 
and the hippocampus, ChR2-YFP did not colocalize with immunoreactivity from 
CGRP neuropeptide, a marker of a PBN input to the BNST (Figure 8A, Figure 8 
B1). I performed image analysis using ImageJ (Fiji) software to illustrate that the 
fluorescent signal from CGRP immunohistochemistry staining that surrounds 
dBNST cell bodies does not overlap with ChR2-YFP fluorescence in Thy1-COP4 
mice. A representative image of this analysis is shown in Figure 8 B2.  
I prepared ex vivo slices from Thy1-COP4 transgenic mice and performed 
optical field potential recordings in the dBNST (Figure 8A). I found that full-field 
optical stimulation in BNST slices from Thy1-COP4 mice produced a 
synchronized field potential response that was substantially reduced by AMPA 
receptor antagonists (76.2% from baseline, n=1), which is consistent with N2 
responses that we have previously published (Egli et al., 2005; Grueter and 
Winder, 2005).  This indicates only a small amount of expression of ChR2 in 
postsynaptic BNST neurons in this mouse line and that the optical field potential 
elicited is driven by recruitment of glutamatergic afferents.  I found that I was able 
to elicit optical field potentials (oN) that were similar in size to our previously 
published N2 responses (inset, Figure 8C) (Egli et al., 2005; Grueter and Winder, 
2005). Surprisingly, when I applied guanfacine (1 µM) to the optical extracellular 
field potential recordings, I observed an increase in the size of the oN (Figure 6C) 
(18.6% ± 6.5%, t(6)=2.9, p<0.05, n=7). This increase in field potential size with 
guanfacine (1 µM) contrasts with our previous work done using electrical  
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Figure 8. Guanfacine increases field potentials in the dBNST of Thy1-COP4 
transgenic mice. A) Illustrated mouse indicating that the experiments done in 
Figure 6 used Thy1-COP4 transgenic mice. B) Image of dorsal BNST (63x) 
showing lack of colocalization of CGRP (red) with ChR2 (green) in Thy1-COP4 
mice. NeuN staining is shown in blue (B1). Representative image of ImageJ (Fiji) 
analysis done of a BNST cell and its surrounding neuropil in a Thy1-COP4 
transgenic mouse. ImageJ (Fiji) image analysis does not show colocalization of 
CGRP (red) with the ChR2 (green). There is also no observed colocalization of 
CGRP or ChR2 with NeuN (blue) (B2). C) Optical field potential (oN) size is 
increased with guanfacine (1 µM) application in Thy1-COP4 mice (p<0.05, n=7). 
Representative trace of oN is shown (inset). D) Preincubation of ex vivo BNST 
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slices with atipamezole (1 µM) blocks the increase in size of the optical field 
potentials with subsequent guanfacine (1 µM) application (n.s., n=5).  
 
 
 
stimulation that shows a decrease in excitatory transmission with guanfacine 
application (Shields et al., 2009). This increase in optical field potential size with 
guanfacine application to ex vivo BNST slices of Thy1-COP4 mice was blocked 
by pre-incubation of slices with atipamezole (1 µM) further confirming this 
enhancement is mediated through activation of α2-ARs (Figure 6D) (0.1% ± 
5.2%, t(4)=0.02, n.s., n=5). 
 
Discussion 
Here I have optogenetically activated PBN inputs to the BNST for 
electrophysiological analysis.  I find that full-field illumination of ex vivo BNST 
slices that have been prepared from mice with AAV5-CaMKIIα-ChR2:YFP 
injected into the PBN at least 5 weeks prior yields a dual component oEPSC that 
produces cell-type specific responses.  In one cell type, stimulation promotes 
robust feed-forward inhibition.  In another, stimulation produces repetitive firing.  I 
found that the α2A-AR agonist guanfacine filters excitatory drive into the BNST by 
depressing oEPSCs contributing to the depolarizing effects of the PBN input. 
Using immunoelectron microscopy and a novel knock-in HA-tagged α2A-AR 
mouse strain, we show that α2A-ARs are present on asymmetric axosomatic 
synapses in the dorsal BNST, which are consistent with localization to PBN 
inputs.  
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α2A-ARs specifically modulate excitatory PBN inputs to the extended amygdala 
In contrast to the PBN input to the BNST, our data suggest that the BLA 
input to the BNST is largely insensitive to guanfacine.  These data are consistent 
with previous work examining the sensitivity of electrically-evoked PBN and BLA 
inputs to the CeA (Delaney et al., 2007). Similar to our findings in the BNST, this 
work suggests that the PBN input to the CeA is depressed by α2-ARs while the 
BLA is unaffected (Delaney et al., 2007). While the relative expression of α2A-
ARs on the BLA terminals in the BNST is unknown, our study suggests that 
these terminals are insensitive to α2A-AR activation.  
Until the advent of optogenetic approaches, studies in which specific 
inputs to the BNST are targeted using electrical stimulation were not possible 
due to the close proximity of afferent fibers to the BNST. Through the use of ex 
vivo slice ChR2 recordings, we are now able to dissect neural circuits in ways 
that were previously not feasible by targeting individual inputs using optogenetic 
strategies outlined in this study. Here, I focus on the selective modulation of a 
PBN input to the dorsal BNST by α2A-ARs because past behavioral work has 
shown that α2-AR agonists in the dorsal BNST block stress-induced relapse to 
drug seeking behavior (Wang et al., 2001). However, recent work has shown that 
the PBN projects to the CeA and the vlBNST with differing densities (Bienkowski 
and Rinaman, 2013). In future work, it may be interesting to more closely study 
the impact of the PBN input to these regions on synaptic transmission. Here I 
demonstrate that optogenetic strategies can be utilized to explore 
neuromodulation of excitatory synapses from selective inputs to the BNST ex 
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vivo.  
 
α2-ARs Regulate Axosomatic Synapses in the Extended Amygdala and in the 
Cerebellum 	  
This work in the context of other studies suggests similarity in PBN control 
of extended amygdala neurons and in climbing fiber control of Purkinje cells.  
First, the PBN input to the BNST shares anatomical features with the climbing 
fiber input in the cerebellum with heavy axosomatic innervation (Eccles et al., 
1966; Shimada et al., 1989).  Second, both generate two types of responses 
upon stimulation: pronounced firing or feed-forward inhibition (Mathews et al., 
2012).  Third, both inputs are selectively regulated relative to other glutamate 
afferents in the respective regions by α2-ARs (Carey and Regehr, 2009).   
I observed that the PBN-initiated current-clamp responses in BNST have 
differential sensitivity to guanfacine. Both the multiple types of post-synaptic 
responses in the BNST to PBN stimulation and the variable sensitivity of these 
responses to guanfacine highlight the complex microcircuitry of the BNST. The 
BNST is composed of many cell types (Hammack et al., 2007), therefore it is not 
surprising that these post-synaptic responses show variable sensitivity to 
guanfacine, in particular the feed-forward PBN-inhibited responses where 
sensitivity of the intermediary interneuron to guanfacine is also a factor. These 
data suggest that guanfacine administration may preferentially filter inhibition of 
one cell type over activation of another by the PBN.  In future studies, 
determining the nature of these neurons, in particular whether they are projection 
neurons or interneurons, will begin to provide a more complete picture of how 
	   63 
this circuit is regulated. Further, I cannot rule out the possibility of infection by the 
ChR2-expressing viral vector of CGRP-negative projections from the PBN to the 
BNST that could influence these responses in unforeseen ways. 
 
Evidence for a Possible Excitatory Role of α2A-ARs in the BNST  
To my surprise, I observed an increase in the size of an optically-induced 
field potential by guanfacine in Thy1-COP4 mice.  These mice have no observed 
colocalization of the neuropeptide CGRP, a marker of one PBN input to the 
BNST, with ChR2-YFP and have very low postsynaptic expression of ChR2 in 
the BNST, suggesting that α2A-ARs may enhance the actions of another 
excitatory input to the BNST.  As shown in Figure 5, we do observe expression of 
the α2A-ARs on other presynaptic terminal types.  Another possibility is that post-
synaptic α2A-ARs in the BNST may increase excitability of BNST cells. For 
example, post-synaptic α2A-ARs can increase excitability by modulation of Ih, as 
has been shown in the prefrontal cortex (Wang et al., 2007). Furthermore, i.p. 
injections of guanfacine increase c-fos expression in the BNST, suggesting a 
possible excitatory role for α2A-ARs (Savchenko and Boughter, 2011), though 
other mechanisms could underlie the increase in c-fos expression with i.p. 
injection of guanfacine. Finally, it is also possible that guanfacine is decreasing 
GABAB signaling or increasing glutamatergic signaling from another input. We 
will further discuss the putative excitatory role for α2A-ARs in the second chapter 
of this dissertation. 
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The PBN Input May Influence Downstream BNST Signaling 
Because of the behavioral effects of activation of α2A-ARs in the BNST, it 
seems likely that the depression of the PBN input to the BNST by guanfacine that 
we observe here may alter downstream signaling of the BNST to brain regions 
involved in addiction and relapse such as the VTA (Georges and Aston-Jones, 
2001, 2002; Dumont and Williams, 2004; Silberman et al., 2013) and the NAc 
(Dong et al., 2001). Alterations in the BNST’s outputs may curb stress-induced 
drug cravings or stress-induced re-emergence of negative symptoms of 
withdrawal. In fact, it has been shows that guanfacine treatment reduces 
withdrawal-induced anxiety in rats treated with guanfacine (Buffalari et al., 2012). 
Additionally, it has been shown that injection of an α2-AR agonist into the BNST 
will block withdrawal-induced place aversion (Delfs et al., 2000). Therefore, a 
decrease in excitatory transmission from the PBN to the BNST by α2A-ARs may 
decrease the aversive withdrawal-like symptoms brought on by stress and help 
to prevent relapse. 
In addition to stress-induced relapse to drug-seeking behaviors, the 
modulation of BNST signaling by the PBN input may influence anxiety-like 
behaviors and fear-conditioning (Sink et al., 2011; Sink et al., 2013b; Sink et al., 
2013a; Gungor and Pare, 2014). The PBN input to other regions of the extended 
amygdala has been implicated in feeding behavior (Carter et al., 2013) and pain 
sensitization (Han et al., 2005; Han et al., 2010). The PBN efferents have also 
been implicated in taste aversion (Mungarndee et al., 2006) and hypercapnic 
arousal (Kaur et al., 2013). Therefore, the optogenetic strategies outlined in this 
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study for the targeting of PBN inputs to the extended amygdala and other brain 
regions could be beneficial in better understanding a wide range of conditions, 
from anxiety disorders, to disorders of energy homeostasis, to pain disorders, to 
sleep apnea. 
In summary, this work demonstrates divergent actions of the PBN input on 
cell responses in the BNST.  I demonstrate that depolarizing effects of the PBN 
appear to be preferentially reduced by the α2A-AR agonist guanfacine.  Finally, 
we show that in the relative absence of PBN signaling, guanfacine has very 
different actions on BNST excitability, suggesting a state-dependent aspect to 
the actions of guanfacine.  In future work, it will be important to examine the 
consequences of specific regulation of the PBN in vivo by guanfacine. 
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CHAPTER III 
 
α2A-Adrenergic Receptors Can Increase Postsynaptic Responses to 
Excitatory Inputs to the Bed Nucleus of the Stria Terminalis 
 
Introduction 
 The bed nucleus of the stria terminalis (BNST) is a brain region that is 
shown to play a critical role in stress-induced relapse to drug-seeking behavior 
(Briand et al., 2010). α2-AR agonists are capable of blocking stress-induced 
reinstatement of drug-seeking behavior in rats with both peripheral administration 
(Erb et al., 2000; Shaham et al., 2000; Highfield et al., 2001; Mantsch et al., 
2010) and also with direct administration into the BNST (Wang et al., 2001). 
Recent clinical studies support therapeutic potential for α2-AR agonists, as α2-AR 
agonists have shown promise in curbing cravings in drug-addicted individuals 
(Sinha et al., 2007; Jobes et al., 2011; Fox and Sinha, 2014; Fox et al., 2014). 
However, the efficacy of the α2A-AR agonist guanfacine in preventing stress-
induced relapse of drug-seeking in humans has not been as great as predicted 
by rodent models (Fox and Sinha, 2014; Fox et al., 2014). 
 This diminished efficacy of guanfacine in preventing relapse may be due 
to competing actions of guanfacine-mediated α2A-AR activation in the BNST. The 
multiple effects of α2A-AR in the BNST include: a presynaptic decrease in 
norepinephrine release, a presynaptic decrease in excitatory transmission from 
the PBN input to the BNST as discussed in chapter 1, increased postsynaptic 
response to other glutamatergic inputs which will be discussed in this chapter, 
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and a postsynaptic population of α2A-ARs on BNST neurons whose actions need 
further investigation. In particular, the increased postsynaptic response to other 
glutamatergic inputs by α2A-ARs is a novel finding in the BNST (Flavin et al., 
2014). However, it has previously been shown in the PFC that postsynaptic α2A-
ARs can enhance excitability of PFC neurons through downstream closing of 
HCN channels (Wang et al., 2007). Therefore, while an excitatory action of α2A-
ARs in the BNST is relatively novel, α2A-ARs have been shown to have excitatory 
actions in other parts of the brain. It is not known whether this excitatory action of 
α2A-ARs in the BNST complements the described decrease in excitatory 
transmission to the BNST (Chapter II) in preventing stress-induced relapse of 
drug-seeking behavior (Shields et al., 2009; Flavin et al., 2014), or if these 
actions work at cross purposes. Therefore, it will be important to further 
investigate the mechanism and timing of the excitatory actions of α2A-ARs in the 
BNST, as further understanding this mechanism could help in increasing the 
efficacy of guanfacine in preventing stress-induced relapse of drug-seeking. 
In summary, while there are multiple roles of α2A-ARs in the BNST, it is not 
yet understood whether these actions work together to influence stress-induced 
relapse behavior or whether these actions contend with each other. I hope that a 
better understanding each of these roles of α2A-ARs in the BNST will allow for   
more selective targeting of guanfacine therapy in humans to increase the efficacy 
of guanfacine in preventing stress-induced relapse of drug-seeking in addicts. In 
this chapter, I will further investigate a potential excitatory role for α2A-ARs in the 
BNST. 
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Evidence for several effects of guanfacine in the BNST 
 Recent evidence suggests that the less-than-expected efficacy of 
guanfacine in preventing stress-induced relapse in addicted individuals may be 
due to multiple, possibly competing, effects of guanfacine in the BNST 
(Savchenko and Boughter, 2011; Flavin et al., 2014).  Previous work has shown 
that α2-AR agonists depress excitatory transmission in the BNST (Egli et al., 
2005; Shields et al., 2009; Flavin et al., 2014). However, recent work shows an 
increase in c-fos expression with i.p. injection of the α2A-AR agonist guanfacine 
(Savchenko and Boughter, 2011). Further, field potential recordings done in 
Thy1-COP4 mice that do not show colocalization of ChR2 with CGRP in the 
BNST have an increase in excitatory optical field potentials with guanfacine 
application (Flavin et al., 2014) (Figure 8). Taken together, these data indicate an 
increased postsynaptic response of α2A-ARs in the BNST to other glutamatergic 
inputs. This chapter will seek to further investigate this excitatory role for α2A-ARs 
in the BNST. 
 
Guanfacine may increase c-fos expression in the BNST through several possible 
mechanisms 	  
There are several possible mechanisms that could account for this 
increase in c-fos expression in the BNST. First, an increase in excitatory 
transmission from one or more inputs to the BNST may be responsible for the 
increased c-fos expression. This increase in excitatory transmission from a 
particular input to the BNST may be masked by the large PBN input during field 
potential recordings (Flavin et al., 2014).  
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Another possibility is that α2A-ARs increase the intrinsic excitability of a 
specific population of cells in the BNST. For example, it has been shown in the 
prefrontal cortex that guanfacine can increase intrinsic excitability of PFC cells 
through α2A-AR-mediated closing of post-synaptic HCN channels (Wang et al., 
2007). A similar mechanism may be occurring in the BNST, as it has been shown 
that certain types of BNST cells express mRNA from HCN channels (Hammack 
et al., 2007; Hazra et al., 2011).  
Finally, it is possible that guanfacine decreases inhibitory transmission 
from GABAB inputs. The GABAA antagonist picrotoxin was bath applied during 
the field potential recordings in the Thy1-COP4 mice (Figure 8), so modulation of 
GABAA transmission by guanfacine can be ruled out as a mechanism. However, 
a decrease in GABAB inhibitory transmission could lead to an increase in c-fos 
expression by downstream relief of inhibition on this population of cells.  
It is important to understand the properties of the population of BNST 
neurons that are activated by α2A-ARs, as these neurons may influence 
transmission of projections from the BNST to stress and reward circuitry and 
modulate stress-induced reinstatement behavior. I will be testing the hypothesis 
that a population of BNST neurons is activated by α2A-ARs and explore the 
properties of this neuronal population.  In this chapter, I will first investigate 
whether guanfacine-mediated depression of excitatory transmission in electrical 
field potential recordings is preserved in slices in which I observe enhancement 
of optical field potentials. This would suggest that certain inputs that are 
stimulated in these electrical recordings, but not in the optical recordings, might 
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mask the excitatory effect of guanfacine. I will next replicate the finding that i.p. 
guanfacine increases c-fos expression in the BNST and then try to characterize 
this population of neurons through electrophysiological recordings and 
immunohistochemistry. Finally, I will address the possible mechanisms for 
increased c-fos expression and increased field potential size with guanfacine as 
described above.  
 
Methods 
 
Fluorescent Immunohistochemistry 
For colocalization studies of c-fos-eGFP with CGRP and calbindin, 4 
transgenic c-fos-eGFP mice (Barth et al., 2004) (B6.Cg-Tg(Fos/EGFP)1-3Brth/J, 
The Jackson Laboratory) were transcardially perfused with 10 mL of ice-cold 
phosphate-buffered saline (PBS), followed by 20 mL of ice-cold 4% 
paraformaldehyde in PBS. Brains were post-fixed in 4% paraformaldehyde 
overnight at 4°C and were then transferred into 30% sucrose and stored for 2 to 
10 days at 4°C. Coronal sections of were cut on a cryostat (Leica, CM3050S) at 
a thickness of 40 µM. Sections containing the BNST were free-floated in PBS for 
immuno-labeling. Sections were permeabilized for 30 minutes with 0.5% Triton-X 
100 in PBS at room temperature (RT). Next, non-specific binding was blocked 
with 10% normal donkey serum in PBS containing 0.1% Triton-X-100 for one 
hour at RT. Sections were then incubated in primary antibody in PBS containing 
0.1% Triton-X-100 for 2 days at 4°C, followed by 4 x 10 minute PBS washes.  
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Sections were then incubated overnight at 4°C with secondary antibodies in PBS 
containing 0.1% Triton-X-100. Finally, sections were washed with PBS (4 x 10 
minutes), mounted on Fisher + slides (Fisher Scientific) and coverslipped with 
PolyAquamount (Polysciences).   
Prior to transcardial perfusion, the c-fos-eGFP mice were handled for 5 
days. The three final of the handling days included saline injections in order to 
habituate mice to injections such that the likelihood of any increase in c-fos-
eGFP expression being due to stress from injections rather than guanfacine 
effects was reduced. 
Images of fluorescent marker-labeled brain sections were taken with a 
Zeiss 710 confocal microscope.  Lenses used included a 20X/0.80 N.A. Plan-
Apochromat and a 63X/1.4 N.A. Plan Apochromat oil. Excitation/emission 
wavelengths (nm) for each fluorophor were; Dylight 405, 405/410-505; YFP, 
512/519-553; cy3, 561/566-600; cy5, 633/638-759. Mosaic image stitching was 
done with Zeiss ZEN software.  
 
Diaminobenzidine (DAB) Immunohistochemistry 
Eight, 4-month-old male C5BL/6 mice were used, with four mice in each 
treatment group. Prior to treatment, the mice underwent a progressive handling 
regimen for 5 days, as previously described by our lab in efforts to reduce stress 
due to injections on treatment day (Olsen and Winder, 2010). After 5 days of 
handling, mice were given an i.p. injection of guanfacine (Tocris) at a dose of 1 
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mg/kg 90 minutes prior to transcardial perfusion. Control mice were given an 
equivalent amount by volume of saline 90 minutes prior to transcardial perfusion. 
Mice were transcardially perfused as described above and 40 µm coronal 
brain slices were prepared for DAB immunohistochemistry. Sections containing 
the BNST were free-floated for immunolabeling. Sections were be blocked with 
5% normal goat serum containing 0.1% Trition-X-100 in PBS. Sections were then 
incubated in primary antibody (Fos antibody anti-rabbit, EMDBiosciences) at a 
concentration of 1:20,000 for 2 days at 4° C, followed by incubation with goat-
anti-rabbit-biotinylated secondary antibody (Vector) for 90 minutes at RT. 
Sections were then incubated in avidin-biotin-complex solution (Vector) for 60 
minutes at RT. Finally, DAB staining was developed with the DAB Kit (Vector). 
Stained sections were mounted on slides and allowed to dry overnight. Stained 
sections were sealed with mounting media (Permount) the following day.  For 
data analysis, manual cell counts were done while blinded to treatment condition 
in a 0.25 mm² square in the ventrolateral region of the dorsal BNST, using 
Metamorph software. Statistical analysis with unpaired student’s t-test was done 
with Prism software.   
 
Electrophysiology Recordings in the BNST 
Brain slice preparation 
Brain slice preparation methods were used as previously described 
(Grueter and Winder, 2005; Grueter et al., 2006). Mice were removed from 
colony and allowed to rest for one hour in a Med Associates sound-attenuating 
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chamber. Following the hour of rest, mice were anesthetized with isofluorane and 
then decapitated. Brains were removed quickly and transferred to a 1-4°C 
oxygenated, low sodium sucrose dissecting solution (in mM: 194 sucrose, 20 
NaCl, 4.4 KCl, 2 CaCl2, MgCl2, 1.2 NaH2PO4, 10 glucose, 26 NaHCO3). A Leica 
vibratome was used to prepare coronal brain slices (300 µm) containing the 
dorsal BNST. Slices were then transferred to either an interface chamber for field 
potential recordings or to a holding chamber for whole cell recordings.  Both the 
interface chamber and the holding chamber contained heated, oxygenated 
artificial cerebral spinal fluid (ACSF) that was composed of (in mM): 124 NaCl, 
4.4 KCl, 2.5 CaCl2, 1.3 MgSO4, 1 NaH2PO4, 10 glucose, 26 NaHCO3. 
 
Alternating field potential recordings 
For field potential recordings, Thy1-COP4 transgenic mice of at least 5 
weeks in age were used.  Slice preparation for field potential recordings in the 
dlBNST was performed as previously reported (McElligott and Winder, 2008).  
Picrotoxin (25 µM) was added to all recordings to isolate excitatory transmission. 
For alternating electrical-optical field potential recordings, light stimulation was 
produced from a Lamba XL light source (Sutter instruments) and shone through 
a bandpass filter (Semrock, 475 nm wavelength, 20 nm bandwidth). The blue 
light was guided from the light source through a water-shielded cable that was 
positioned approximately 5 cm above the surface of the slice, resulting in full-field 
illumination. The light stimulation produced a shift in potential, the optical field 
potential (oN) that was shown to be NBQX sensitive (decreased 76% from 
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mean), similar to the N2 seen in electrical field potential recordings previously 
described (Weitlauf et al., 2004; Egli et al., 2005). In alternating electrical-optical 
field potential recordings, the electrical portion of the field potential recording was 
performed as previously described (McElligott and Winder, 2008). pClamp 
software (Axon Instruments) controlled light and electrical pulse duration and 
frequency. Light stimuli were approximately 2 ms in duration and occurred every 
40 seconds. Electrical stimulation occurred every 40 seconds and alternated with 
the optical stimulation such that the slice received either electrical or optical 
stimulation once every 20 seconds. 
 
Analysis of field potential recordings 
All field potential recordings were analyzed via Clampfit 9.2 (Molecular Devices) 
as previously described (Shields et al., 2009). All field recordings contain a 20 
min baseline prior to agonist application and all data points are normalized to the 
baseline 5 minutes prior to agonist application. Plotted time courses for field 
experiments are represented as one-minute averages. 
  
Whole cell recordings 
Current clamp whole cell Recordings in c-fos-eGFP mice 
Transgenic c-fos-eGFP mice (Barth et al., 2004) (B6.Cg-Tg(Fos/EGFP)1-
3Brth/J, The Jackson Laboratory) were injected with 1 mg/kg of guanfacine 
(Tocris) 90 minutes prior to brain slice preparation, as previously described (Egli 
and Winder, 2003; Grueter and Winder, 2005), to induce c-fos-eGFP expression 
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in the BNST. The excitable membrane properties of c-fos-eGFP-expressing 
BNST neurons were characterized in a manner similar to that previously 
published by our lab (Egli and Winder, 2003). It has been previously shown that 
populations of cells in the BNST can be characterized using their electrical 
properties (Egli and Winder, 2003; Dumont and Williams, 2004; Hammack et al., 
2007). Recordings were done in current clamp mode at the neurons’ resting 
membrane potential and we tested the response of the neuron’s membrane 
potential to positive and negative current injections in a manner similar to as 
described above for BNST neurons innervated by the PBN.  Neurons were 
depolarized to characterize action potential firing threshold and frequency. 
Neurons were also hyperpolarized by tonic current injection to look for the 
presence of a depolarizing sag with hyperpolarization (Egli and Winder, 2003; 
Hammack et al., 2007). 
 
Voltage clamp whole cell Recordings in c-fos-eGFP mice 
Using electrical stimulation, I assessed the response of c-fos-eGFP 
positive BNST neurons to subsequent ex vivo application of guanfacine. 
Transgenic c-fos-eGFP mice were injected with guanfacine and prepared for 
electrophysiological recordings as described above. Electrically-evoked EPSCs 
were recorded from c-fos-eGFP positive neurons in the dorsal BNST as 
described previously by our lab (Shields et al., 2009). Ex vivo guanfacine (Tocris) 
was applied at a concentration of 1 µM for 10-20 minutes. Excitatory 
transmission was isolated by bath application of 25 µM picrotoxin throughout the 
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duration of the experiment. Student’s paired t-test was then used to determine if 
guanfacine had a significant effect by comparing baseline values to the changes 
induced by guanfacine.   
All whole cell data were recorded with Clampex version 10.2 and analyzed 
with pClamp version 10.2 (Molecular Devices). Recordings contained a 5 to 10 
minute baseline recording prior to drug application. All data points were 
normalized to the first 5 minutes of baseline. Plotted time courses for whole-cell 
experiments are represented as 30 second averages.  
 
Statistics 
Experiments comparing a difference to baseline were analyzed using a 
student’s T-test. Experiments with multiple drug treatments were analyzed using 
a One-way repeated measures ANOVA and a Geisser-Greenhouse correction. 
Experiments comparing baseline levels of c-fos positive neurons to guanfacine-
treated c-fos positive neurons in IHC experiments were done using an unpaired 
T-test. Results are reported in text and figure legends. Significant differences 
were defined as having a P<0.05. 
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Results 	  
Decrease in stimulation of PBN input to the BNST reveals excitatory actions of 
α2A-AR activation 	  
As discussed in Chapter 1 of this dissertation, in examining ChR2-YFP 
expression in Thy1-COP4 transgenic mice, I determined that while ChR2-YFP 
was heavily expressed in regions that project to the BNST such as the BLA, 
cortical regions, and the hippocampus, ChR2-YFP did not co-localize with 
CGRP-immunoreactivity in the BNST (Figure 8). This lack of colocalization 
between ChR2-YFP and CGRP suggested that PBN axons in the region would 
not be recruited by blue-light stimulation in the BNST, while cortical, amygdalar, 
and other afferents would be activated. I prepared ex vivo slices from Thy1-
COP4 transgenic mice and attempted to perform optical field potential recordings 
in the dBNST. I found that full-field optical stimulation in BNST slices from Thy1-
COP4 mice produced a synchronized field potential response that was 
substantially reduced by AMPA receptor antagonists (76.2% from baseline), 
which is consistent with N2 responses that we have previously published and 
indicates low, if any, postsynaptic expression of ChR2 (Egli et al., 2005).  This 
indicates only a small amount of expression of ChR2 in postsynaptic BNST 
neurons in this mouse line and that the optical field potential elicited is driven by 
recruitment of glutamatergic afferents.  I found that I was able to elicit optical field 
potentials (“oN”) that were similar in size to our previously published N2 
responses (Egli et al., 2005). Given the lack of co-localization between ChR2-
YFP with CGRP, as well as and the lack of heavy post-synaptic ChR2 
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expression, this Thy1-COP4 mouse allowed us to begin to look at guanfacine 
effects on non-PBN afferents into the BNST. 
I applied guanfacine (10 µM) to “alternating” field potential recordings, in 
which optical stimulation of the ex vivo BNST slice was alternated with electrical 
stimulation of the slice. In these alternating field potential recordings, an 
enhancement of the oN was seen (Figure 9A) (9.8% ± 2.9%, t(5)=3.3, p<0.05, 
n=6) in the same slices that we observed a depression of the electrical field 
potential (Figure 9B) (29.5% ± 7.4%, t(5)=3.96, p<0.02, n=6). Therefore, 
guanfacine produces an enhancement of field potential size with optical 
stimulation that of inputs that show no colocalization of CGRP with ChR2-YFP, 
likely indicating a substantial reduction of PBN afferent stimulation, and a 
depression of glutamatergic transmission in field responses with electrical 
stimulation that includes the PBN. These results may indicate that the large, 
axosomatic PBN input masks a potential excitatory role for α2A-ARs in the BNST. 
 
Intraperitoneal guanfacine increases c-fos expression in the dorsal BNST 
Next, I examined the findings of Savchenko et al. (2010) that showed that c-fos 
expression in the BNST is significantly increased with i.p. injection of guanfacine. 
In the work done by Savchenko et al. (2010), the mice were not handled or 
habituated to injection prior to i.p. injection of guanfacine and transcardial  
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Figure 9. Alternating electrical and optical stimulation of the BNST in Thy1-
COP4 mice yields two different responses. A. Guanfacine application to 
optical field potential recordings in the BNST of Thy1-COP4 mice leads to an 
increase in field potential size. B. Guanfacine application to electrical field 
potential recordings in the BNST of Thy1-COP4 mice leads to a decrease in field 
potential size. 
 
 
 
perfusion. Therefore, it is possible that the increase in c-fos expression that was 
seen was due to stress experienced with injection. I tried to control for injections 
in our experiment by handling the mice five days prior to i.p. injection of 
guanfacine and transcardial perfusion. The five-day handling paradigm included 
20 40 60 80 100
0
25
50
75
100
125
150
175
Time (minutes)
%
 B
as
el
in
e 
N
2
20 40 60 80 100
0
25
50
75
100
125
150
175
Time (minutes)
%
 B
as
el
in
e 
oN
	   80 
three days of exposure to injection through i.p. saline injections. I performed 
diaminobenzidine (DAB) IHC staining for c-fos in free-floated slices prepared 
from transcardially perfused mice that received an i.p. injection of guanfacine two 
hours prior to killing. I saw a significant increase in c-fos expression in the BNST 
after i.p. injection of guanfacine as compared to saline-injected animals (t(6)=2.7, 
n=8, p<0.05), consistent with previous Savchenko et al. (2010) (Figure 10).  
 
                             
 
Figure 10. In vivo α2A-AR agonists activate dorsal BNST neurons. A. 
Enhancement of c-fos expression in the dorsal BNST after i.p injection of 
guanfacine (1 mg/kg) as compared to saline injection (p=0.03). B. c-fos staining 
in dorsal BNST of saline injected mouse. C. c-fos staining in dorsal BNST of 
guanfacine injected mouse. 
 
 
 
Characterization of c-fos-eGFP cells in the BNST after in vivo guanfacine 
 Once I established that there is a significant increase in expression of c-
fos in the BNST of guanfacine-injected animals as compared to saline-injected 
animals, I next sought to characterize this population of cells that express c-fos in 
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response to i.p. guanfacine. We used both fluorescent immunohistochemistry 
and current clamp whole cell analyses to try to find common characteristics of the 
population of cells in the BNST that expresses c-fos in response to i.p. 
guanfacine injection.  
Previous work suggests that neurons in the BNST can be divided into sub-
groups according to electrophysiological characteristics (Egli and Winder, 2003; 
Dumont and Williams, 2004; Hammack et al., 2007). In trying to identify the 
electrophysiological properties of BNST neurons that are activated by in vivo 
administration of guanfacine, I made use of transgenic c-fos-eGFP mice. These 
c-fos-eGFP mice were made in the Barth lab and express GFP under the control 
of the activity dependent c-fos gene (Barth et al., 2004). These transgenic mice 
express a c-fos-eGFP fusion protein when the c-fos gene is turned on with cell 
activity (Barth et al., 2004). I handled each of these transgenic mice for the five 
days prior to recordings in the same manner that I handled the mice prior to 
transcardial perfusion for DAB staining as described above. I then injected the 
transgenic mice with i.p. guanfacine (1 mg/kg) ninety minutes to two hours prior 
to ex vivo slice preparation. During my electrophysiological recordings, I injected 
step-wise depolarizing and hyperpolarizing currents into the cell while recording 
in current clamp configuration (Figure 11). I found that c-fos-eGFP positive cells 
that I record from displayed Ih currents at hyperpolarizing potentials and fire 
rapidly at depolarizing potentials (Figure 11). The resting membrane potentials of 
the c-fos-eGFP cells rested between -60 mV and -80 mV. 
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I also sought to determine if staining for certain fluorescent 
immunohistochemical markers would help us to identify the population of c-fos-
eGFP neurons. Prior work suggests that subpopulations of BNST neurons can 
also be classified based on expression of neuropeptides (Day et al., 1997; Day et 
al., 1999; Day et al., 2001; Day et al., 2005), such as corticotrophin releasing 
factor (CRF). CRF signaling has previously been demonstrated by our lab 
 
                                       
 
Figure 11. Representative traces of step-wise current injection into c-fos-
eGFP positive cell. Two hours after i.p. guanfacine injection (1 mg/kg) c-fos-
eGFP positive cells in the BNST were injected with step-wise hyperpolarizing and 
depolarizing current and cell responses were recorded. The majority of cells 
displayed Ih current with hyperpolarizing current steps and fired with depolarizing 
current steps. 
 
to modulate NE signaling in the BNST (Nobis et al., 2011). Calbindin is 
expressed in inhibitory neurons in the BNST (Fudge and Haber, 2001; Gos et al., 
2013). In order to facilitate the fluorescent staining, I perfused transgenic c-fos-
500 ms
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eGFP mice that had been handled for 5 days prior to transcardial perfusion, as 
has been described above for DAB staining. Ninety minutes to two hours prior to 
perfusion, the mice received an i.p. injection of guanfacine (1 mg/kg) in order to 
induce c-fos-eGFP expression in the guanfacine-activated cell population. I also 
injected another set of handled c-fos-eGFP mice with saline as a control group. 
After transcardial perfusion, we prepared free-floating slices for 
immunohistochemistry staining. We then stained one set of BNST slices for 
calbindin and another set of BNST slices for CGRP. We found that some of the 
c-fos-eGFP colabeled for calbindin (Figure 12), while others did not. There were 
very few colabeled cells in the guanfacine-injected group as well as in the saline 
injected group. We also saw some c-fos-eGFP cells that were surrounded by 
CGRP staining while others did not (Figure 12). Again, there were comparable 
levels of CGRP-surrounded c-fos-eGFP cells in guanfacine-injected versus 
saline-injected mice. Altogether, these data suggest a heterogeneity of the c-fos–
eGFP positive cells in the BNST after i.p. guanfacine. 
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Figure 12. C-fos-eGFP positive cells in the BNST do not colabel with CGRP 
or calbindin staining. A. Staining of c-fos-eGFP positive BNST cells (green) are 
sometimes surrounded by CGRP staining (purple) ninety minutes after 
guanfacine injection (1 mg/kg, i.p.) (white arrow). B. C-fos-eGFP positive cells 
(green) sometimes colocalize with calbindin staining (red) ninety minutes after 
guanfacine injection (1 mg/kg, i.p.). Colocalization is shown with white arrow. 
 
 
 
Ex vivo guanfacine application decreases excitatory transmission to c-fos-eGFP 
positive cells after in vivo guanfacine 	  
The increase in c-fos expression with in vivo guanfacine suggests an α2A-
AR-mediated increase in postsynaptic response to some glutamatergic inputs. I 
first hypothesized that the c-fos-eGFP positive cells that are activated by in vivo 
guanfacine are activated by an increase in excitatory transmission from a 
particular input to the BNST. To test this hypothesis, I prepared ex vivo brain 
slices from transgenic c-fos-eGFP mice that had been injected with i.p. 
guanfacine (1 mg/kg) ninety minutes to two hours prior to slice preparation. 
These mice were also handled for five days prior to recording, as described 
above.  
A. B. 
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I performed whole-cell voltage clamp recordings using electrical 
stimulation of the stria terminalis, a fiber bundle that carries afferent fibers to the 
BNST, and recorded in the presence of picrotoxin (25 µM) to isolate excitatory 
transmission. I then bath-applied guanfacine to voltage-clamped whole cell 
recordings of EPSCs from c-fos-eGFP cells. I saw that EPSCs decreased in size 
with guanfacine application to ex vivo slices, indicating a decrease in excitatory 
transmission to c-fos-eGFP positive cells (Figure 13) (54.4% ± 3.0%, t(6)=18.0, 
p<0.001, n=7). Because there are some cells in the BNST that express c-fos 
basally without i.p. guanfacine treatment, I made sure to look for variability in 
guanfacine sensitivity among the c-fos-eGFP cells from which I recorded, since 
inputs to the c-fos-eGFP cells that are c-fos-eGFP positive basally may be 
differentially modulated by ex vivo guanfacine application compared to cells that 
express c-fos-eGFP in response to α2A-AR activation, and I do not know whether 
the c-fos-eGFP cells I record from basally express c-fos-eGFP or are expressing 
c-fos-eGFP in response to i.p. guanfacine. However, I saw little variability among 
recordings and noted that excitatory transmission to c-fos-GFP positive cells 
decreased with ex vivo guanfacine application across all experiments (N=7). 
 
	   86 
                     
 
Figure 13. Ex vivo guanfacine decreases excitatory transmission to c-fos-
eGFP positive cells in the BNST. Voltage clamp whole cell recordings were 
done from c-fos-eGFP positive cells in the BNST of ex vivo brain slices prepared 
two hours after guanfacine injection (i.p., 1 mg/kg). Bath application of 
guanfacine to recordings resulted in decreased excitatory transmission to these 
c-fos-eGFP positive cells. 
 
 
 
We noted that it was possible that we did not see any changes in 
sensitivity to ex vivo guanfacine application because of alterations in α2A-AR 
sensitivity due to prior i.p. guanfacine treatment. However, I have found that the 
effects of guanfacine on electrical field potential recordings in the in the BNST 
are readily reversible with subsequent atipamezole treatment (Figure 14A) 
(F(2,5)=1.53, n.s., n=6). The effects of guanfacine do not reverse without 
subsequent atipamezole treatment (Figure 14B) (32.8% ± 9.9%, t(3)=3.3, p<0.05, 
n=4). Additionally, i.p. injection with an alternate α2-AR agonist clonidine prior to 
ex vivo brain slice preparation does not occlude subsequent depression of 
excitatory transmission by ex vivo guanfacine (Figure 15) (30.1% ± 6.6%, 
t(5)=4.6, p<0.01, n=6), as compared to depression of  excitatory transmission 
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Figure 14. Guanfacine depression is reversible with α2-AR antagonist 
atipamezole. A) Field potential recordings done with electrical stimulation reveal 
that guanfacine will decrease excitatory transmission in the BNST and that this 
depression is reversed by subsequent atipamezole. B). The decrease in 
excitatory transmission caused by guanfacine will not reverse with prolonged 
washout with normal ACSF. 
 
 
 
seen in naïve ex vivo brain slices that are treated with guanfacine (32.8% ± 
9.9%, t(3)=3.3, p<0.05, n=4). These data together suggest that it less likely that 
in vivo guanfacine permanently altered excitatory transmission prior to ex vivo 
recordings since α2A-AR-mediated depression of excitatory transmission is 
readily reversible (Figure 14) and i.p. clonidine also does not alter sensitivity to 
subsequent guanfacine (Figure 15). Therefore, it seems unlikely that the increase 
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in c-fos-eGFP expression with i.p. guanfacine is due to α2A-AR-mediated 
increases in excitatory transmission from particular inputs to this population of 
cells.  
 
                                
 
Figure 15. Prior intraperitoneal injection with clonidine does not occlude 
depression of excitatory transmission by subsequent guanfacine. There is 
no observed difference in the depression of excitatory transmission in electrical 
field potential recordings in wild-type mice that had been injected with clonidine 
thirty minutes prior to ex vivo brain slice preparation versus naïve mice. 
 
 
 
Discussion 
 In our exploration of Aim 2 of this dissertation, I found two pieces of 
evidence that further support a potential excitatory role for α2A-ARs in the BNST 
that I first observed in Figure 7 of Chapter 1 of this dissertation. First, I found that 
I was able to observe guanfacine-mediated enhancement of optical field 
potentials within the same Thy1-COP4 slices that I observe depression of 
electrical field potentials. Since Thy1-COP4 mice have no observed 
colocalization of CGRP and ChR2-YFP, these data seem to indicate that 
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excitatory effects of α2A-ARs can be discerned when there is a relative lack of 
stimulation of the PBN afferents to the BNST. I also saw that, even with the 
addition of five days of handling and acclimation to injections, there is an 
increase in c-fos expression in the BNST with i.p. injection of guanfacine (1 
mg/kg), consistent with previous findings (Savchenko and Boughter, 2011). Both 
the increased c-fos expression as well as the increased field potential size in 
Thy1-COP4 mice suggest a potential excitatory role for α2A-ARs in the BNST, 
which is unexpected considering that the presynaptic Gi/o-coupled α2A-ARs result 
in a decrease in excitatory transmission in electrically-stimulated field potential 
and whole cell recordings in the extended amygdala (Dumont and Williams, 
2004; Delaney et al., 2007; Shields et al., 2009) through a reduction in 
presynaptic glutamate release (Delaney et al., 2007; Shields et al., 2009).  
I made several attempts to determine the mechanism by which c-fos 
expression is increased in hopes of better understanding the excitatory role of 
α2A-ARs. I performed fluorescent immunohistochemical staining and whole cell 
current clamp electrophysiological recordings in BNST slices prepared from c-
fos-eGFP transgenic mice in an effort to see if the population of c-fos-eGFP 
positive cells had any unifying characteristics. I did not find any common markers 
among the c-fos-eGFP positive cells for either the calbindin staining or the CGRP 
staining that I performed on slices prepared from c-fos-eGFP mice that had 
received i.p. injection of guanfacine (Figure 12).  
I did observe some common electrophysiological characteristics of the c-
fos-eGFP positive cells, including the presence of an Ih current. The presence of 
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the Ih current in the c-fos-eGFP positive cells was consistent with previous work 
that found the presence of HCN1 mRNA in some BNST cell types. The presence 
of the Ih current is also consistent with previous work done in the mPFC that has 
found that signaling through activated α2A-ARs leads to closing of HCN channels, 
which results in an increase in excitability of post-synaptic mPFC pyramidal 
neurons (Wang et al., 2007). Thus, I hypothesized that the increase in c-fos 
expression in the BNST was due to a closing of postsynaptic HCN1 channels 
through α2A-ARs and that this closing of HCN1 channels results in an increase in 
excitability of postsynaptic BNST cells that I was able to detect in optical field 
potential recordings in the absence of PBN input (Figure 8C, 9A). However, I 
found no difference in c-fos expression after i.p. guanfacine injected in HCN KO 
mice versus WT mice (data not shown). There are four forms of HCN channels in 
the BNST, so it is a possibility that another HCN channel besides HCN1 is 
involved in c-fos expression (Barth et al., 2004). This possibility will be discussed 
further in Chapter V. 
I next tested the hypothesis that the increase in c-fos expression was due 
to increased excitatory transmission from a particular glutamatergic input onto 
the c-fos positive cells. I tested this by recording from c-fos-eGFP positive cells in 
BNST ex vivo slices prepared from c-fos-eGFP transgenic mice that had been 
injected with guanfacine (1 mg/kg) and handled for five days prior to slicing. I 
predicted that if excitatory transmission from a particular input to the c-fos-eGFP 
positive cells were increased by α2A-AR activation, I would see an increase in 
excitatory transmission with guanfacine application to electrically-stimulated 
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whole cell voltage clamp recordings. Instead, I saw a decrease in excitatory 
transmission with subsequent ex vivo guanfacine application. Therefore, it seems 
unlikely that the increase in c-fos expression is due to increased excitatory 
transmission from a particular input directly onto the c-fos-eGFP positive cells. It 
is possible that the in vivo guanfacine given ninety minutes prior to slicing altered 
α2A-AR regulation of excitatory transmission, however, this seems unlikely given 
the reversibility of guanfacine actions (Figure 14) and given that i.p. clonidine 
treatment does not alter subsequent ex vivo guanfacine application (Figure 15). 
While initial attempts to determine the mechanism of a potential excitatory role 
for α2A-ARs in the BNST have been unsuccessful, the future work proposed in 
the Future Directions section of this dissertation may lead insights into the 
excitatory role of α2A-ARs.  
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CHAPTER IV 	  
Discussion and Future Directions 	  
Adrenergic receptors in the BNST influence stress-induced relapse of drug-
seeking behavior 	  
Evidence implicates ARs in the extended amygdala in stress-induced 
reinstatement of drug-seeking behavior, with behavioral data showing that β- and 
α1-AR antagonists can block stress-induced reinstatement of drug-seeking (Leri 
et al., 2002; Mantsch et al., 2010; Le et al., 2011; Vranjkovic et al., 2012), while 
α2-AR agonists block reinstatement (Wang et al., 2001).  α2-ARs mediate 
transient depression of excitatory transmission and appear to differentially 
modulate excitatory inputs to the extended amygdala (Delaney et al., 2007; 
Flavin et al., 2014). Differential modulation would allow for certain inputs to 
dominate regulation of synaptic transmission in the extended amygdala 
depending on the neural context of information reaching the BNST. Integration of 
inputs to the extended amygdala and modulation of neural activity within the 
region allow ARs to regulate stress-induced reinstatement of drug-seeking. α2A-
ARs also appear to have multiple other functions in the BNST including an 
excitatory role, modulation of norepinephrine release, and postsynaptic 
expression whose function has not yet been explored. Therefore, α2A-ARs 
appear to have complex actions in the BNST that require further study in order to 
understand the role of each of these functions in stress-induced relapse of drug-
seeking behavior. 
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While some of the key ARs underlying stress-induced relapse to drug-
seeking behavior have been identified, there is still work to be done in 
understanding the specific mechanisms of stress-induced relapse. In particular, 
there is a need for an understanding of the particular afferent and efferent 
connections of the BNST that may be modulated by specific ARs. Delaney et al., 
2007 have shown that the PBN and BLA inputs to the CeA appear to be 
differentially modulated by α2-ARs, and I have shown that the PBN and BLA 
inputs to the BNST are differentially regulated by α2A-ARs (Flavin et al., 2014). It 
is quite possible that many of the extended amygdala’s inputs and outputs are 
differentially modulated by ARs. An understanding of such differential modulation 
would further elucidate the specific neural circuitry underlying stress-induced 
relapse.  
Additionally, the BNST is composed of a heterogenous population of cells, 
including interneurons and projection neurons. Various types of ARs may 
differentially regulate excitability of these numerous cell types within the BNST. 
Both differential modulation of afferents to the BNST and differential excitability of 
various cell types within the BNST may influence regulation of the BNST’s 
projections neurons. A deeper understanding of how ARs affect the strength of 
the BNST’s downstream projections may elucidate some of the key components 
of the neural circuitry that are engaged during stress-induced reinstatement of 
drug-seeking. Thus, investigation of how ARs regulate synaptic transmission in 
the extended amygdala may also shed light on the therapeutic potential for α1- 
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and β-antagonists and α2-agonists in preventing stress-induced relapse to drug-
seeking.  
 
Excitatory transmission from PBN afferents to the BNST is regulated by 
α2A-ARs 	  
In my work done on Aim 1, I used optogenetic strategies to target the PBN 
input to the BNST for electrophysiological analysis.  I found that optical 
stimulation of ChR2-expressing PBN afferents in ex vivo BNST slices yielded a 
dual component oEPSC that produced two types of cell-type specific responses.  
I found that the PBN input to the BNST innervated two potential cell types. In one 
cell type, stimulation produced robust feed-forward inhibition.  In the other, 
stimulation produced repetitive firing.  I found that the α2A-AR agonist guanfacine 
filtered excitatory drive into the BNST by depressing oEPSCs contributing to the 
depolarizing effects of the PBN input. Using immunoelectron microscopy of the 
knock-in HA-tagged α2A-AR mouse strain, we demonstrated that α2A-ARs are 
present on asymmetric perisomatic synapses, which is consistent with 
localization to PBN inputs. I also found that removal of the PBN input to the 
BNST, as indicated by a lack of colocalization of CGRP and ChR2-YFP in the 
BNST of the Thy1-COP4 mice, reveals a secondary, possibly excitatory, role for 
guanfacine in the BNST. 
 
The release of CGRP neuropeptide from the PBN may influence synaptic 
transmission in the BNST 	  
 An important future direction for Aim 1 will be to further understand the 
	   95 
effects of the PBN input to the BNST on the microcircuitry of the BNST and to 
study the impact of the PBN input to BNST on downstream BNST signaling. In 
order to examine the impact of the parabrachial nucleus input on BNST circuitry, 
one of the possible next steps will be to investigate whether release of the CGRP 
neuropeptide from PBN terminals influences the post-synaptic BNST cell firing. 
We will also need to further elucidate which types of BNST cells are being 
innervated by the PBN. 
The PBN input to the BNST is largely glutamatergic, but the PBN can 
release CGRP from many of its terminals with appropriate stimulation (Gungor 
and Pare, 2014). It is possible that the different responses of postsynaptic BNST 
cells that we see in current clamp (i.e. PBN-excited versus PBN-inhibited) may 
be partially due to by CGRP release.  A differential regulation of these two types 
of responses by CGRP could have downstream effects on BNST inputs to other 
regions of the brain involved in stress and reward.  
For example, it is possible that the strong firing observed in PBN-activated 
responses is due to a release of the CGRP neuropeptide. The PBN-activated 
cells may receive CGRP signaling while the PBN-inhibited do not. In fact, it may 
be the case that if we block the synaptic transmission of the CGRP neuropeptide 
in the BNST that we will shift the previously observed ratio of PBN-inhibited to 
PBN-activated responses (Figure 4).  Intense postsynaptic firing produced by 
CGRP neuropeptide signaling may be mask a PBN-inhibited type response in 
some cases, making it look like a PBN-activated type response.  
In order to further investigate the role of CGRP signaling in the BNST we 
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will be able to make use of the Calca-Cre mouse line (McCoy et al., 2013). The 
Calca-cre mouse line expresses Cre recombinase under the CGRP promoter, 
Calca. Therefore, by injecting a DIO-ChR2 virus into the PBN we will be able to 
selectively target ChR2 expression to CGRP-expressing neurons in the PBN. We 
will then be able to record in ex vivo slices of dorsal BNST using light stimulation 
of the ChR2 that will be targeted to the CGRP-expressing PBN input to the BNST 
and look at changes in PBN-inhibited versus PBN-activated cell populations.  
 
Further classification of types of BNST neurons that receive PBN input 
Further classifying the types of neurons in the BNST that are innervated 
by the PBN and determining how each of these types is influenced by PBN 
stimulation may help us to understand how the PBN input to the BNST influences 
downstream signaling of the BNST. We have already attempted to classify the 
BNST cells that are innervated by the PBN by their electrophysiological 
characteristics (Figure 4) and their sensitivity to guanfacine (Figure 7). We could 
further classify these neurons based upon their morphology, which we would be 
able to examine through cell filling experiments. We could also investigated 
whether each of the classes of neurons are projection neurons or interneurons. 
 To determine which of the cells innervated by the PBN are projection 
neurons we could inject retrograde tracer beads into some of the known 
downstream targets of BNST projection neurons, such as the NAc (Dong et al., 
2001) and the VTA (Georges and Aston-Jones, 2001, 2002; Dumont and 
Williams, 2004). In these same animals we could then inject AAV-CaMKIIα -
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ChR2-YFP into the PBN. We would then transcardially perfuse some of these 
animals to look for ChR2-YFP-labelled axosomatic innervation of BNST 
projection neurons that are labeled by retrograde tracer beads that have been 
injected into either the VTA or the NAc. This would give us some initial evidence 
that projection neurons receive inputs from the PBN.  
We could also record from BNST projection neurons that have been 
labeled by the retrograde tracer beads from one of the downstream BNST 
targets. We could optically stimulate the PBN input to these projection neurons to 
determine their response to PBN stimulation. It is possible that projection 
neurons in the BNST comprise one of the two types of neurons that we found to 
be innervated by the PBN, such as the PBN-inhibited or the PBN-activated 
populations. Recording from retrogradely-labeled BNST projection neurons while 
stimulating the PBN input onto these neurons will help us to determine whether 
projection neurons show both PBN-inhibited and PBN-activated responses to 
PBN stimulation or only one type of response. If projection neurons from a 
particular downstream target only show one type of response, it may then be the 
case that another type of cell, such as interneurons or projection neurons to 
another brain region, comprises the other population. Further studying the effects 
of the PBN input on different classes of BNST neurons, such as projection 
neurons, and the α2A-AR regulation of the PBN input onto these classes of 
neurons, will help us to better understand the influences of α2A-AR-regulation of 
the PBN input on the downstream signaling of the BNST. Such studies may help 
us to elucidate the neural circuitry that underlies the ability of α2-ARs in the BNST 
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to block stress-induced reinstatement of drug-seeking in rodent models. 
 
α2-AR regulation of the PBN input to the BNST may regulate induction of 
depolarization-induced suppression of excitation 	  
Prior work has shown that in the cerebellum α2-ARs on axosomatic 
terminals can influence depolarization-induced suppression of excitation (DSE) 
(Carey and Regehr, 2009). In the cerebellum, the axosomatic climbing fiber input 
has been shown to innervate purkinje cells (Mathews et al., 2012). α2-ARs have 
been shown to decrease synaptic transmission from the axosomatic climbing 
fiber input to purkinje cells (Carey and Regehr, 2009) analogous to the α2A-AR-
induced depression of transmission from the PBN to the BNST (Flavin et al 
2014). It has further been shown that α2-ARs regulate the induction of DSE in the 
climbing fiber input to the cerebellum with activation of α2-ARs blocking the 
induction of DSE (Carey and Regehr, 2009). It would be interesting to examine 
whether the α2A-ARs regulate induction of DSE for the axosomatic PBN input to 
the BNST, as it would demonstrate a possible physiological action of α2A-AR 
regulation of the PBN input to the BNST that would have important 
consequences of downstream signaling of the BNST to other stress and reward 
centers in the brain, such as the VTA (Georges and Aston-Jones, 2001, 2002; 
Dumont and Williams, 2004) and NAc (Dong et al., 2001). In vivo, it has been 
shown that endocannabinoid signaling and noradrenergic signaling interact with 
one another to influence stress-induced reinstatement of drug-seeking behavior 
in rodent models (Vaughn et al., 2012). Evidence suggests that cannabinergic 
and noradregergic signaling may work synergistically to mediate stress-induced 
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reinstatement of drug-seeking, as i.p. injection of a cannabinoid agonist together 
with an α2-AR antagonist will induce reinstatement of drug-seeking, even at 
doses that would not induce reinstatement if the drugs were given individually 
(Vaughn et al., 2012). Taken together, both the evidence of α2-ARs regulation of 
DSE induction in the cerebellum, a region of the brain where α2A-ARs may 
regulate climbing fiber inputs analogously to the regulation of the PBN inputs to 
the BNST, and the evidence of in vivo synergistic influences of cannabinergic 
and noradrenergic signaling on stress-induced reinstatement of drug-seeking 
indicate the need for further studying α2A-AR control of DSE in the BNST. If α2A-
AR activation in the BNST can regulate DSE, this finding may be important in 
mechanistically understanding the ability of α2-AR activation in the BNST to block 
stress-induced reinstatement of drug-seeking. If interactions of α2A-ARs and 
endocannabindoids are found in the BNST, this mechanism may help us in more 
effectively targeting guanfacine treatments to prevent stress-induced relapse in 
human populations. 
 
Guanfacine may influence stress-induced reinstatement of conditioned 
place preference in mice 	  
It will also be important to study the influences of the PBN input to the 
BNST and its regulation by α2A-ARs on stress-induced reinstatement of drug-
seeking in rodent models. Thus far, α2-AR agonists have only been shown in rat 
behavioral models to block stress-induced reinstatement of drug-seeking (Erb et 
al., 2000; Highfield et al., 2001; Wang et al., 2001; Mantsch et al., 2010), 
however, since I have been using mouse models for our electrophysiological 
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recordings, it is important that we be able to replicate the ability of α2-AR agonists 
to block stress-induced reinstatement of drug-seeking in mice. I have attempted 
to block stress-induced reinstatement of conditioned place preference (CPP) for 
cocaine with i.p. guanfacine injections, but the results were inconclusive (see 
Appendix Figure 16). Therefore, we should first repeat our efforts to show a block 
of stress-induced reinstatement of drug-seeking with guanfacine treatment in 
mice.  
 
The effect of selective ablation of CGRP neurons in the PBN on stress-
induced reinstatement of conditioned place preference in mice 	  
Once we establish a block of stress-induced reinstatement of place 
preference with guanfacine in mice, we can then look more specifically at the 
PBN’s role in stress-induced reinstatement. We can do this through the use of a 
Calca-DTR mouse line, which expresses the human diphtheria toxin receptor 
under the promoter for the CGRP gene. We can inject this Calca-DTR virus into 
the PBN of WT mice so that CGRP-positive neurons in the PBN then express the 
human diphtheria toxin receptor, thus making those cells susceptible to 
subsequent i.p. diphtheria toxin injections, which will kill any cells that express 
the human diphtheria toxin receptor. Therefore, we will be able to selectively 
lesion CGRP-expressing neurons in the PBN of WT mice. Once we have 
reinstatement working again in our CPP assay in WT mice, we can then compare 
stress-induced reinstatement of place preference in WT mice as compared to 
mice that have had CGRP-expressing neurons in the PBN selectively lesioned. 
While lesioning of CGRP-expressing neurons in the PBN would lesion all of the 
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efferent CGRP-releasing projections from the PBN, not just the PBN projection to 
the BNST, it may provide initial insight into whether the CGRP-expressing PBN 
neurons are essential for stress-induced relapse to drug seeking behavior.  
 
In vivo studies may allow for better understanding of the role of the PBN on 
stress-induced reinstatement of drug-seeking behavior 	  
To more specifically look at the PBN input to the BNST and its role in 
stress-induced reinstatement of drug-seeking, we could use in vivo optogenetic 
approaches. In order to mimic the depression of the glutamatergic PBN input to 
the BNST by guanfacine, we could inject a halorhodopsin virus under the control 
of the CaMKIIα promoter into the PBN. We could then implant a yellow light 
source into the BNST so that light stimulation is selectively targeting the PBN 
afferents to the BNST. We could then run conditioned place preference for 
cocaine and determine if inhibiting the PBN input to the BNST with activation of 
halorhodopsin blocks stress-induced reinstatement of conditioned place 
preference after extinction. 
We could also study the effect of globally decreasing transmission from 
the PBN to its downstream projections in the brain through the use of DREADDs 
(Designer Receptor Exclusively Activated by Designer Drug). In this dissertation, 
I demonstrate that excitatory transmission from the PBN input to the BNST can 
be decreased by activation of the α2A-AR, which belongs to the Gi/o GCPR family. 
If we inject a transgene that expresses a Gi/o DREADD into the PBN of wild type 
mice, we could then use an i.p. injection of the designer drug that activates the 
DREADD to study the effect that the decrease in transmission from the PBN to 
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its downstream target has on stress-induced reinstatement. This use of the Gi/o 
DREADD would allow us an analogous way to study the effect of guanfacine on 
synaptic transmission from the PBN to its downstream targets. Such an approach 
could allow us to determine if guanfacine effects on transmission from the PBN is 
plays a critical role stress-induced reinstatement of drug-seeking behavior.  
 
Effects of heterosynaptic α2A-ARs on anxiety behaviors 
 Our lab has recently acquired a transgenic line of mice that is a KO of α2A-
ARs and α2C-ARs and also overexpresses α2A-ARs under the dopamine beta 
hydroxylase (DBH) promoter. Since DBH is only expressed on norepinephrine 
synaptic terminals and the other α2A-ARs and α2C-ARs are eliminated, only the 
α2A-ARs autoreceptors are expressed in this mouse under the control of the DBH 
promoter. However, initial electrophysiological analyses suggest that the 
expression of the α2A-ARs on the NE terminals may not completely restore NE 
signaling through other adrenergic receptor types in the BNST (Appendix Figure 
20). After further characterization of NE signaling in these transgenic mice, we 
could run general anxiety tests on these mice and compare them to WT mice to 
see if there are any difference in anxiety levels between mice that have 
heterosynaptic α2A-ARs versus those that only have autoreceptor α2A-ARs. Some 
of the initial anxiety tests that we could run include elevated plus maze (EPM) as 
well as open field testing to look at differences in center time.  
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The PBN input to the extended amygdala may influence a range of 
behaviors 	  
In addition to stress-induced relapse to drug-seeking behaviors, the 
modulation of BNST signaling by the PBN input may influence anxiety-like 
behaviors and fear-conditioning (Sink et al., 2011; Sink et al., 2013b; Sink et al., 
2013a; Gungor and Pare, 2014). The PBN input to other regions of the extended 
amygdala has been implicated in feeding behavior (Carter et al., 2013) and pain 
sensitization (Han et al., 2005; Han et al., 2010). The PBN input to other regions 
of the brain has been implicated in taste aversion (Mungarndee et al., 2006) and 
hypernapnic arousal (Kaur et al., 2013). Therefore, the optogenetic strategies 
outlined in this study for the targeting of PBN inputs to the extended amygdala 
and to other brain regions could be beneficial in better understanding a wide 
range of conditions, from anxiety disorders, to disorders of energy homeostasis, 
to pain disorders, to sleep apnea. 
 
The PBN input to the BNST may be relevant to anxiety behaviors 
The actions of CGRP in the BNST have been shown to influence anxiety-
like behaviors in rodent models (Sink et al., 2011; Sink et al., 2013b; Sink et al., 
2013a). The effects of CGRP on anxiety appear to be at least partially dependent 
on signaling through CRFR1 receptors in the BNST (Sink et al., 2013b). Further, 
recent work has shown that CGRP effects inhibitory signaling within the BNST by 
increasing the amplitude of evoked IPSPs (Gungor and Pare, 2014). In future 
work, it may be interesting to study the effects of guanfacine on BNST neurons 
that specifically receive innervation from CGRP-expressing PBN terminals in the 
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BNST. One could investigate if CGRP-expressing PBN terminals in the BNST 
are preferentially regulated by α2A-ARs. One could also investigate if CGRP-
expressing PBN terminals selectively innervate the PBN-inhibited BNST cell 
population described in Chapter 1 (Figure 4), as it has been recently shown that 
CGRP in the BNST modulates inhibitory signaling (Gungor and Pare, 2014). 
Such studies may reveal insights into neurocircuitry involved in anxiety. 
Therefore, the implications of this study may extend beyond stress-induced 
relapse to drug-seeking behavior and may open new directions for studying 
mechanisms underlying anxiety-like behaviors.  
 
Optogenetic approaches may increase understanding of how PBN input to the 
central nucleus of the amygdala influences pain sensitization 	  
 CGRPR1 receptors in the central nucleus of the amygdala have been 
previously shown to play an important role in pain sensitization in rodent models 
(Han et al., 2005). Further, CGRPR1 antagonists were found to reverse arthritis 
pain-related plasticity in the lateral capsular CeA (Han et al., 2005). CGRP has 
been shown to enhance excitatory synaptic transmission in the lateral capsular 
CeA (Han et al., 2010), while stereotaxic injection of CGRP in the CeA has been 
shown to increase pain sensitization in rodent models (Han et al., 2010). 
Therefore, since CGRP is a neuropeptide released by the PBN input to the 
extended amygdala (Dobolyi et al., 2005) and CGRP in the CeA has been shown 
to affect both synaptic transmission and pain sensitization behaviors, the use of 
optogenetic strategies to specifically stimulate the PBN input to the CeA could 
further increase our understanding of the neural circuitry underlying pain 
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sensitization. Both ex vivo and in vivo optogenetic strategies could be used to 
further dissect the role of the PBN and its projections to the extended amygdala 
in mediating pain sensitization. 
 
The PBN input to the BNST may influence feeding behavior 
 Recent work has shown that the PBN input to the CeA influences feeding 
behavior (Carter et al., 2013). In particular, optogenetically-targeted activation of 
CGRP-containing neurons from the lateral PBN that project to the CeA 
suppresses appetite (Carter et al., 2013). While the PBN input to the BNST was 
not implicated in feeding behavior in this particular study (Carter et al., 2013), 
circuitry involving the BNST may play a role in diet failure, analogous to the role 
that it plays in addiction relapse (Wang et al., 2001; Briand et al., 2010). In this 
study, the CGRP-containing PBN input to the BNST was stimulated and this 
stimulation was not shown to alter feeding behavior (Carter et al., 2013). 
However, depression of this CGRP-containing input to the BNST was not tested 
and may influence feeding behavior. Further, there are PBN inputs to the BNST 
that do not contain CGRP (Niu et al., 2010; Kaur et al., 2013; Flavin et al., 2014), 
and modulation of these inputs may influence feeding behavior. The BNST has 
been implicated in mediating some of the negative symptoms of withdrawal 
(Delfs et al., 2000), and similar symptoms may contribute to diet failure. 
Therefore, the ex vivo optogenetic strategies outlined in this paper may increase 
our understanding of the neural circuitry underling some aspects of feeding 
behavior. 
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Ex vivo optogenetic strategies may increase understanding of the PBN regulation 
of hypercapnic arousal 
  
 Glutamatergic neurons in the lateral PBN have been shown to mediate 
arousal during hypercapnia (Kaur et al., 2013). For example, it was shown that 
genetic deletion of Vglut2 from lateral PBN neurons increases latency to arousal 
with hypercapnia in rodent models (Kaur et al., 2013). However, the lateral PBN 
projects to many brain regions (Saper and Loewy, 1980; Fulwiler and Saper, 
1984; Delaney et al., 2007; Flavin et al., 2014) and it is not yet known which of 
these PBN projections are involved in hypercapnic arousal. Optogenetic 
strategies that study the PBN efferents to different brain regions in isolation could 
help to identify which elements of the PBN circuitry contribute to hypercapnic 
arousal, which could be in treating disorders such as sleep apnea. 
 
The PBN influences taste aversion behavior 
Previous work has shown that the lateral PBN is involved in taste aversion 
behaviors (Mungarndee et al., 2006). More specifically, lesioning of the lateral 
PBN ablates the viscerosensory neurons in the PBN, which subsequently 
prevents the viscerosensory malaise caused by food poisoning from reaching the 
forebrain (Mungarndee et al., 2006). Additionally, lesioning of the medial PBN 
prevents the association of taste with the malaise caused by food poisoning 
(Mungarndee et al., 2006).  
Since the lateral PBN provides information regarding viscerosensory 
malaise to the forebrain, it is possible that one of roles of the PBN input to the 
extended amygdala is to relay information regarding the negative symptoms of 
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withdrawal, such as malaise, to the extended amygdala. Therefore, it will be 
interesting in the future to test if lesioning of the lateral PBN can block 
withdrawal-induced place aversion, which would further indicate that the lateral 
PBN plays a role in processing negative symptoms of withdrawal. To more 
specifically test the PBN afferents to the BNST, future work could include 
halorhodopsin injection into the lateral PBN accompanied by a yellow light source 
implantation into the BNST. Then, PBN afferent expressing halorhodopsin could 
be specifically inhibited using the yellow light source and one could test if 
inhibiting this input to the BNST prevents withdrawal-induced place aversion in 
rodent models. 	  	  
Future work is needed to understand the possible excitatory role of α2A-
ARs in the BNST 	  
In my work on Aim 2, I was able to confirm previous findings that i.p. 
injection of guanfacine (1 mg/kg) increases c-fos expression in the BNST 
(Savchenko and Boughter, 2011). However, the i.p. route of guanfacine 
administration produces systemic effects that make it difficult to determine a 
specific mechanism of increased c-fos expression. Therefore, my first goal was 
to try to find common characteristics of the population of BNST neurons that 
increase c-fos expression with in vivo guanfacine.  I hoped that determining 
common characteristics of this population of c-fos neurons would help guide us 
to the mechanism by which c-fos expression was induced. Ultimately, identifying 
this population of neurons may allow us to better understand the possible 
excitatory role of α2A-ARs and the BNST and elucidate how these neurons might 
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influence the BNST’s downstream projections to stress and reward circuitry. I 
hope that by understanding both the input-specific decrease in excitatory 
transmission of the PBN input to the BNST by α2A-AR activation and the 
excitatory role of α2A-ARs in the BNST that we will better understand how α2A-AR 
agonists, such as guanfacine, could be used to prevent stress-induced relapse in 
human populations.	  
 The increase in c-fos expression in the BNST with i.p. injection of 
guanfacine (1 mg/kg) is consistent with previous findings (Savchenko and 
Boughter, 2011) and considered together with Figure 8 from Chapter 1, and 
Figure 9 from chapter it, it seems that there is a possible excitatory role for α2A-
ARs in the BNST, which contrasts with previous findings showing that α2A-ARs 
decrease excitatory transmission in the BNST through a presynaptic mechanism 
(Shields et al., 2009).  
I attempted to define the mechanism by which c-fos expression is 
increased in the BNST by α2A-ARs in Chapter 2. I performed fluorescent 
immunohistochemistry and whole cell current clamp recordings in an attempt to 
identify to any unifying characteristics of the c-fos positive cell population. We did 
not find any common markers in either the calbindin or the CGRP staining that 
we performed (Figure 12). I did observe the presence of an Ih current in the c-fos-
eGFP positive cells, which was consistent with previous work showing the 
presence of HCN1 mRNA in some BNST cell types. The Ih current I observed 
was also consistent with previous work done in the mPFC that has found that 
signaling through activated α2A-ARs leads to closing of HCN1 channels, which 
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results in an increase in excitability of post-synaptic mPFC pyramidal neurons 
(Wang et al., 2001). Thus, I hypothesized that in the increase in c-fos expression 
in the BNST was due to a closing of postsynaptic HCN1 channels through α2A-
AR signaling. However, I found no difference in c-fos expression after i.p. 
guanfacine injected in HCN KO mice versus WT mice (data not shown).  
I next tested the hypothesis that the increase in c-fos expression was due 
to increased excitatory transmission from a particular glutamatergic input onto 
the c-fos positive cells. I recorded from c-fos-eGFP positive cells in BNST slices 
prepared from transgenic mice that had been injected with guanfacine (1 mg/kg) 
prior to slicing. I observed a decrease in excitatory transmission with subsequent 
ex vivo guanfacine application, making it unlikely that the increase in c-fos 
expression was due to increased excitatory transmission from a particular input 
directly onto the c-fos-eGFP positive cells. While initial attempts to determine the 
mechanism of a potential excitatory role for α2A-ARs in the BNST have been 
unsuccessful, some of the future work outlined in this chapter may lead to new 
mechanistic insights. 
 
C-fos positive cells may be characterized by expression of CRF or ENK 
neuropeptides 	  
Calbindin is a marker that has been used in the BNST as a marker of 
GABAergic interneurons (Gos et al., 2013). We also know from the work 
described in Chapter 1 of this dissertation that the PBN afferent to the BNST 
forms axosomatic synapses (Shimada et al., 1985; Shimada et al., 1989; Dobolyi 
et al., 2005). Therefore, I investigated whether the c-fos positive cells 
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demonstrated either significant levels of colocalization with calbindin, indicating 
that it was likely an interneurons population, or if a significant amount of outlining 
with CGRP staining, indicating that they were highly innervated by the PBN. 
However, when I compared guanfacine-injected animals with saline-injected 
animals I saw no noticeable difference in either the amount of colocalization with 
calbindin or in the outlining with CGRP terminals.  
Since my initial studies immunohistochemistry studies did not reveal any 
specific markers for the c-fos positive cell population in the BNST, the next step 
will be to pursue methods to characterize this population of neurons by 
neuropeptide expression of the c-fos positive cell. However, this initial indication 
of heterogeneity of c-fos expressing neurons may suggest complex downstream 
modulations of BNST projections to stress and reward circuitry with α2A-AR 
activation. 
 Prior work suggests that subpopulations of BNST neurons can be 
classified based on expression of neuropeptides (Day et al., 1999; Day et al., 
2001; Day et al., 2005), such as corticotrophin releasing factor (CRF) and 
enkephalin (ENK). CRF signaling has previously been demonstrated by our lab 
to modulate NE signaling in the BNST (Nobis et al., 2011). ENK-expressing 
neurons in the BNST increase c-fos mRNA expression after exposure to drugs of 
abuse (Day et al., 2001) and this increased c-fos expression is prevented by prior 
exposure to stress (Day et al., 2005). Therefore, it is possible that the cell 
population in the BNST that expresses c-fos in response to guanfacine will show 
high levels of colocalization with either CRF or ENK. Our lab currently breeds a 
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CRF-Rosa transgenic mouse line. In the future, it may be possible to cross a c-
fos-eGFP transgenic mouse with a CRF-Rosa mouse to generate c-fos-
eGFP(+)/CRF-Rosa(+) mouse line. We would then look for a significant increase 
in colocalization of CRF-Rosa and c-fos-eGFP in mice that are injected with 
guanfacine (1 mg/kg) as compared to those that are injected with saline.  
If we do not see any significant colocalization between CRF-Rosa and c-
fos-eGFP, we could then pursue staining with ENK antibodies. Again, we would 
look for a significant increase in colocalization of c-fos with ENK in mice that had 
been injected with guanfacine versus those that had been injected with saline. By 
doing our initial fluorescent IHC with calbindin and CGRP, we attempted a 
broader classification of the c-fos positive neurons. Staining for neuropeptides in 
the future may help us to more specifically classify these c-fos cells.  
 
Modulation of the HCN1 channel may not account for increased c-fos 
expression 	  
As discussed in Chapter 2 of this dissertation, in addition to looking for 
immunohistochemical marker for guanfacine-sensitive c-fos positive cells within 
the BNST, I also looked at the electrophysiological characteristics of these c-fos 
positive cells. Since c-fos is expressed in the dorsal BNST of saline-treated mice, 
we were sure to record from a large sample size of neurons since some c-fos-
eGFP neurons are not guanfacine-dependent. I recorded from a large sample 
size of recorded neurons to ensure that we record from enough guanfacine-
dependent c-fos-eGFP neurons to discern potential differences between these 
neurons and guanfacine-independent c-fos-eGFP neurons. One of the more 
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interesting electrophysiological characteristics that we observed across all c-fos-
eGFP positive neurons was the presence of an Ih current. 
 The presence of the Ih current in the c-fos-eGFP cells fits with work that 
has been done previously demonstrating that BNST cells express mRNA that 
encodes for HCN channels (Hammack et al., 2007). Additionally, work previously 
done in the PFC has shown that the activation of postsynaptic α2A-ARs can lead 
to the closing of HCN channels that increases the excitability of the postsynaptic 
cell (Wang et al., 2007). We hypothesized that a similar scenario could be 
happening in the BNST. For example, guanfacine could be closing postsynaptic 
HCN channels through downstream α2A-AR signaling, leading to increase in 
excitability of the postsynaptic cell. This increase in excitability of the 
postsynaptic cells would account for both the c-fos expression in the cell as well 
as the increase size of the optical field potential that we observe (Figures 8, 9), 
since field potential recordings can detect both changes in synaptic transmission 
as well as effects on general cell population excitability.  
 In order to test the hypothesis that closing of HCN channels was 
responsible for the increase in c-fos expression in the BNST with i.p. guanfacine, 
I took advantage of an HCN1 KO mouse line. I expected that if closing of HCN1 
channels was responsible for the increase in c-fos expression that I would see a 
dramatic decrease in c-fos expression with guanfacine treatment in HCN1 KO 
mice as compared to WT mice. I would also expect to see that c-fos levels were 
very similar between HCN1 KO mice that had been treated with guanfacine as 
compared to HCN1 KO mice that had been treated with saline, and that c-fos 
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expression in both of these conditions would be very low. Yet, I did not detect a 
noticeable difference in levels of c-fos expression when comparing guanfacine-
treated HCN1 KO mice to guanfacine-treated WT mice (data not shown). Further, 
I observed that guanfacine-treated HCN1 KO displayed noticeably higher levels 
of c-fos expression in the dorsal BNST when compared to saline-treated HCN1 
KO mice. These findings together indicate that α2A-AR-mediated closing of HCN1 
channels is not responsible for the increase in c-fos expression seen with 
guanfacine treatment. However, previous work has shown that mRNA encoding 
other types of HCN channels is also expressed in the BNST, including HCN2, 
HCN3 and HCN4 channels (Hammack et al., 2007). I only explored the possibility 
of HCN1 channels being responsible for the increase in c-fos expression, but it is 
possible that closing of one of the other types of HCN channels is responsible for 
the increase in c-fos expression that we see in this population of BNST cells. 
 We could further test the hypothesis that guanfacine increases c-fos 
expression in the BNST by blocking HCN channels through sharp electrode 
recordings of c-fos-eGFP positive cells in the BNST after in vivo guanfacine 
treatment. Whole cell recording of c-fos-eGFP cells in ex vivo BNST slices could 
be done in which hyperpolarizing steps are given to the cell such that Ih currents 
can be recorded from the cell. We could then bath apply guanfacine to the BNST 
slice and see if the Ih current is reduced by guanfacine treatment. As a positive 
control, the compound ZD7288, a HCN channel blocker, could also be used to 
ensure that these types of recordings allow us to measure reduction in Ih currents 
when HCN channels are pharmacologically blocked. 
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 I attempted these recordings during our work done on Aim 2 using regular 
patch pipettes, but I observed that with 30 minute recordings in normal ACSF, Ih 
currents decreased in size even without guanfacine treatment, suggesting that 
this observed reduction of Ih current is independent of guanfacine. I suspect that 
this reduction in Ih current was due to the dialyzing of components of the Gi/o 
signaling cascade into the pipette tip. However, if similar recordings were done in 
the future using sharp electrodes this dialyzing of intracellular signaling 
components may be prevented. Therefore, with sharp electrode recording 
experiments, I may be able to observe if bath application to ex vivo BNST slices 
reduces Ih current in c-fos-eGFP positive cells after in vivo guanfacine treatment. 
A reduction of Ih current that was similar to a reduction in Ih current following bath 
application of ZD7288 would support the hypothesis that the increase in c-fos 
expression with in vivo guanfacine is due to postsynaptic α2A-ARs blocking HCN 
channels in the c-fos-eGFP positive cells. 
 
Increased excitatory transmission from glutamatergic inputs likely does 
not account for increase in c-fos expression 	  
Since identification of the common electrophysiological characteristic of 
the presence of Ih current in c-fos-eGFP neurons did not lead to a clear 
mechanism by which c-fos expression may have been increased, I hypothesized 
that it may be properties of afferent fibers that regulate c-fos expression with α2A-
AR activation. An increase in excitatory transmission from a particular 
glutamatergic input to a population of c-fos-expressing cells would explain the 
increase in c-fos expression with in vivo guanfacine. The increase in excitatory 
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transmission from a specific input would also account for the increase in size of 
the optical field potentials with guanfacine application to BNST slices prepared 
from Thy1-COP4 mice (Figure 9), since the absence of the stimulation of the 
large PBN input to the BNST in these mice could allow for the effects of 
guanfacine on other smaller inputs to be revealed.  
I did not observe an increase in excitatory transmission to the c-fos-eGFP 
positive neurons with subsequent ex vivo guanfacine application. Instead, I 
observed a decrease in excitatory transmission to the c-fos-eGFP neurons 
(Figure 13). I also monitored holding current and input resistance to determine if 
α2A-ARs grossly change intrinsic excitability properties of the neurons, but did not 
observe any changes. It is a possible that in vivo treatment with the α2A-AR 
agonists changed the electrophysiological properties of the afferent to the 
neurons that are activated by α2A-AR agonists. For example, possibly the α2A-
ARs expressed on the presynaptic terminal did not re-sensitize by the time of 
bath application of guanfacine, thus occluding any further enhancement. 
However, preliminary work from our lab suggests that the effects of α2A-AR 
agonists in the BNST are readily reversible (Figure 14) and that prior i.p. 
injections of a non-selective α2-AR agonist clonidine also does not effect 
subsequent ex vivo guanfacine application (Figure 15). Therefore, I predict that 
α2A-ARs expressed on afferents to these c-fos-GFP positive neurons will be re-
sensitized prior to ex vivo guanfacine application. Therefore, it is unlikely that an 
increase in excitatory transmission from a particular glutamatergic input onto the 
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c-fos-eGFP positive cells is the mechanism underlying the increase in c-fos 
expression after in vivo guanfacine.  
 
Other possible mechanisms for increased c-fos expression 
While the list of possible mechanisms underlying the increase in c-fos 
expression in the BNST that we tested was not exhaustive, I saw no apparent 
indication that I identified the mechanism underlying both the increase in c-fos 
expression with in vivo guanfacine and the increase in optical field potential size 
with ex vivo guanfacine application to BNST slices prepared from Thy1-COP4 
mice. The underlying mechanism does not appear to be a closing of HCN1 
channels or an increase in excitatory transmission from a particular glutamatergic 
input the specifically innervates the c-fos positive neurons. However, there are 
other possible mechanisms in addition to the ones already mentioned in this 
discussion that could be tested in future work.  
 
Alterations in GABAB signaling may account for increase in c-fos expression 
There are several other mechanisms that we could test in future work to 
see if we can determine the way in which c-fos expression is enhanced by 
guanfacine. The absence of enhancement of EPSCs that I observed (Figure 13) 
may indicate that the enhanced c-fos expression is due to a decrease in 
inhibitory transmission in vivo. One possibility is that the increase in c-fos 
expression is due to a decrease in GABAA signaling in vivo that is not detected in 
ex vivo whole cell recordings due to the presence of picrotoxin, a GABAA 
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antagonist. However, decreases in GABAA signaling would not explain the 
increase in optical field potentials that I see with guanfacine application to ex vivo 
Thy1-COP4 slices (Figure 8), since these recordings were done in the presence 
of picrotoxin (25 µM). However, guanfacine has been shown by our lab to 
decrease inhibitory transmission, which may include GABAA transmission 
(Shields et al., 2009). Therefore, while changes in GABAA transmission likely do 
not contribute to the increase in field potentials seen in Figure 8 due to the 
presence of picrotoxin, it may contribute to c-fos expression in vivo. It is possible 
that a decrease in GABAB signaling is responsible for the increase in c-fos 
expression in a population of cells in the BNST through reduced inhibition of 
these cells. We have not yet explored modulations of GABAB signaling by 
guanfacine, but that may be an important future direction to pursue in 
understanding both increases in c-fos expression with in vivo guanfacine as well 
as increases in optical field potential recordings with ex vivo guanfacine 
application to BNST slices from Thy1-COP4 mice. 
 
Increased c-fos expression in the BNST in vivo may be due to multisynaptic 
signaling 	  
Another possibility is that the increase in c-fos expression is due to 
multisynaptic signaling. For example, an increase in activity in another area of 
the brain in vivo could indirectly increase c-fos expression in the BNST by 
multisynaptic signaling that modulates activity in an intervening brain region that 
projects to the BNST. If this were the case, there would be increased c-fos 
expression in a population of BNST cells in vivo, but that I would not be able to 
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detect the increased activity of the upstream brain regions ex vivo, as the 
multisynaptic connections would be lost with brain slice preparation. 
For example, as described previously, guanfacine acting through 
postsynaptic α2A-ARs can close HCN channels and lead to increased excitability 
of postsynaptic pyramidal PFC neurons (Wang et al., 2007). Increased c-fos 
expression in the BNST may be due to increased excitability of pyramidal 
neurons in the PFC after guanfacine treatment, which in turns signals through 
one or more intermediary brain regions to ultimately activate a BNST cell 
population in vivo.  
If this were the case, the increase in c-fos expression would require an 
intact connection between the PFC and all of the intermediary brain regions and 
the BNST, and would therefore only be found on the in vivo level of the mouse. In 
brain slice preparation, the multisynaptic signaling would be lost and the 
increased excitability would therefore by undetectable in ex vivo brain slice 
recordings. 
 In future work, it will be interesting to determine if multisynaptic signaling 
is a likely mechanism for increased c-fos expression. In order to do so, we will 
need to determine if increased c-fos expression is able to occur at the ex vivo 
slice level, thus allowing us to determine if α2A-ARs effects on local circuits within 
BNST slices are sufficient to increase in c-fos expression. If increased c-fos 
expression is not seen in ex vivo brain slices with guanfacine application, it would 
further support the idea that global brain circuits may need to be intact for 
increased c-fos expression, such as the PFC connection through intermediary 
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brain regions to the BNST. However, if increased c-fos expression was seen in 
ex vivo brain slices, it would support the idea that modulation of local circuits in 
the BNST by guanfacine is sufficient to increase c-fos expression in a particular 
cell population. 
 Ex vivo BNST brain slices could be prepared from c-fos-eGFP transgenic 
mice, then time-lapsed imaging could be performed on the BNST slice to record 
images of c-fos-eGFP expression in the BNST with ex vivo guanfacine 
application. If we find that c-fos-eGFP expression increases on the slice level, 
this may indicate that intrinsic BNST circuit effects are sufficient for the increase 
in c-fos expression seen after in vivo guanfacine treatment. However, if we do 
not observe an increase in c-fos-eGFP in an ex vivo slice with guanfacine 
application, it may indicate that intact brain circuits are needed for the increase in 
c-fos expression to be seen in the BNST and thus we would only observe 
increased c-fos expression after in vivo guanfacine treatment. 
There is a population of PFC neurons that project to the BNST and it is a 
possibility that these excited PFC neurons that project directly to the BNST may 
be responsible for the increase in c-fos expression (McDonald et al., 1999). 
However, our whole cell experiments that show a decrease in excitatory 
transmission with guanfacine application to electrical stimulation of inputs to c-
fos-eGFP positive cells (Figure 13), as well as a decrease in excitatory 
transmission with guanfacine application to optical stimulation of Thy1-COP4 
brain slices (Figure 19), indicate that increased excitability of a direct input to 
these c-fos positive cells is unlikely. 
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MAP kinase modulation of Kv4.2 may cause increase in c-fos expression 
Finally, downstream signaling from MAP kinase (MAPK)/extracellular 
signal-regulated kinase (ERK) modulation of the potassium channel Kv4.2 may 
lead to an increase in c-fos expression in the BNST with guanfacine treatment. It 
has been previously shown that Kv4.2 channels are expressed in the BNST 
(Rainnie et al., 2014) and that GPCR signaling can modulate downstream 
MAPK/ERK signaling which regulates Kv4.2 potassium channels (Yuan et al., 
2002; Sweatt, 2004; Hu et al., 2006). It has also been shown that i.p. guanfacine 
increases ERK phosphorylation in BNST neurons (Savchenko and Boughter, 
2011).  Therefore, this increased ERK activity could be leading to downstream 
downregulation of Kv4.2 potassium channels, which could increase excitability of 
the cell. Therefore, since α2A-ARs signal through Gi/o GPCRs, it is possible that 
α2A-AR activation lead to downstream modulation of ERK that alters regulation of 
Kv4.2 potassium channels, leading to increased excitability on of a population of 
cells in the BNST. 
 
Overall Conclusions 
 
The PBN Input May Influence Downstream BNST Signaling 
Due to the behavioral effects of activation of α2A-ARs in the BNST, it 
seems likely that the depression of the PBN input to the BNST by guanfacine 
may alter outputs of the BNST to brain regions involved in addiction and relapse 
such as the VTA (Georges and Aston-Jones, 2001, 2002; Dumont and Williams, 
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2004; Silberman et al., 2013) and the NAc (Dong et al., 2001). Alterations in the 
BNST’s outputs may curb stress-induced drug cravings or stress-induced re-
emergence of negative symptoms of withdrawal. In fact, it has been shows that 
guanfacine treatment reduces withdrawal-induced anxiety in rats treated with 
guanfacine (Buffalari et al., 2012). Additionally, it has been shown that injection 
of an α2-AR agonist into the BNST will block withdrawal-induced place aversion 
(Delfs et al., 2000). Therefore, a decrease in excitatory transmission from the 
PBN to the BNST by α2A-ARs may decrease the aversive withdrawal-like 
symptoms brought on by stress and help to prevent relapse. 
I have also observed an excitatory role for α2A-ARs in the BNST. At this 
time, it is not known whether this excitatory role of α2A-ARs would work to 
complement the depression of excitatory transmission from the PBN input in 
preventing stress-induced relapse or if the excitatory role would oppose the 
effects on PBN transmission. Thus far, the use of guanfacine treatment in human 
populations has decreased cravings in dug-addicted individuals. However, 
overall relapse outcomes have not been improved by guanfacine treatment (Fox 
et al., 2012; Fox and Sinha, 2014; Fox et al., 2014). In the future, it will be 
important to determine the mechanism of this excitatory role of α2A-ARs in the 
BNST and explore the timing of this effect and its relation to the depression of 
excitatory transmission from other afferents such as the PBN. It may be the case 
that more specific targeting of guanfacine therapy to either the excitatory role of 
α2A-ARs or the depression of certain excitatory inputs to the extended amygdala 
will increase the efficacy of guanfacine in preventing stress-induced relapse to 
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drug-seeking behavior.  
In summary, my work demonstrates divergent actions of the PBN input on 
cell responses in the BNST.  I demonstrate that depolarizing effects of the PBN 
appear to be preferentially reduced by the α2A-AR agonist guanfacine.  Finally, I 
show that in the absence of PBN signaling, guanfacine has very different actions 
on BNST excitability, suggesting a state-dependent aspect to the actions of 
guanfacine.  In future work, it will be important to examine the consequences of 
specific regulation of the PBN in vivo by guanfacine. 
The results of our studies may further elucidate how α2A-ARs in the BNST 
modulate stress-induced reinstatement behavior. Using optogenetic approaches, 
we will study individual inputs to the BNST in a manner that has not previously 
possible. I hope the proposed work will increase our understanding of the 
therapeutic potential for α2A-AR agonists for the prevention and treatment of 
stress-induced relapse to drug-seeking.  
 
Directed targeting of guanfacine may be needed to increase clinical efficacy in 
preventing stress-induced relapse of drug-seeking behavior  
 
It has been shown that both peripheral and intra-BNST administration of 
α2-AR agonists can block stress-induced relapse of drug-seeking behavior in 
rodent behavioral models (Erb et al., 2000; Shaham et al., 2000; Highfield et al., 
2001; Wang et al., 2001; Mantsch et al., 2010). However, human clinical trials 
testing the ability of guanfacine to prevent stress-induced relapse of drug-seeking 
have not shown as much success; self-reported drug-cravings are decreased in 
these studies, but overall relapse outcomes are not improved (Fox et al., 2012; 
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Fox and Sinha, 2014; Fox et al., 2014).  The multiple actions of guanfacine-
mediated α2A-AR activation described in this dissertation may account for the 
relative lack of success for guanfacine in clinically treating addiction. 
 Previous work and work done in this this dissertation has demonstrated 
that there are multiple effects of the α2A-AR agonist guanfacine in the BNST. 
First, guanfacine can work on α2A-AR autoreceptors to decrease release of 
presynaptic norepinephrine release. Second, guanfacine decreases excitatory 
transmission from selective inputs to the BNST, such as the PBN, while having 
no apparent effect on transmission from other inputs to the BNST, such as the 
BLA (Flavin et al., 2014). Guanfacine has also been shown to decrease inhibitory 
transmission in the BNST (Shields et al., 2009). Further, α2A-AR activation can 
increase postsynaptic response to other glutamate afferents (Savchenko and 
Boughter, 2011; Flavin et al., 2014). Finally, our EM work revealed a population 
of postsynaptic α2A-ARs whose role in BNST synaptic transmission still needs to 
be evaluated (Flavin et al., 2014). 
 While multiple functions of α2A-ARs in the BNST have been uncovered, it 
is still unknown which of these functions contribute to signaling involved in stress-
induced relapse of drug-seeking behavior. For example, it is unknown whether 
these multiple actions of guanfacine work together to prevent stress-induced 
relapse of drug-seeking behavior in rodents, or if these actions are at cross 
purposes, with some actions with some actions working to prevent stress-
induced relapse while others actions may mitigate such effects. If the multiple 
actions of guanfacine work at cross purposes it may help to explain the 
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decreased efficacy of guanfacine in preventing relapse in clinical trials since the 
beneficial effects of guanfacine may be partially negated by its other effects. 
Therefore, if it can be determined in future work which of these actions of 
guanfacine contribute to the ability of α2-ARs to block stress-induced relapse and 
which actions are not beneficial, we may be able to more selectively target 
treatments to relapse-protective α2A-ARs and increase efficacy of clinical 
prevention of stress-induced relapse.   
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APPENDIX 	  	  
Attempt to block stress-induced reinstatement of conditioned place 
preference with i.p. guanfacine is inconclusive 	  
 
Figure 16. Initial attempt to block stress-induced reinstatement of drug-
seeking with guanfacine is inconclusive. We tested four conditions: i.p. saline 
injection 30 minutes before a priming dose of cocaine, i.p. guanfacine before 
priming dose of cocaine, i.p. saline before forced-swim stress, i.p. guanfacine 
before forced-swim stress. We looked at time spent on the preferred side of the 
two-sided chamber before conditioning (pretest, black dotted bars), after 
conditioned (posttest, black checkered bars), after extinction (posttest 2, 
horizontal striped bars), and immediately after priming cocaine or stress 
(reinstatement, vertical striped bars). However, we did not observe reinstatement 
in either of the control conditions (saline + prime, saline + stress) and therefore 
could not interpret if guanfacine blocked either reinstatement condition. 
 
 The previous behavioral work done in rodent models showing that α2-AR 
agonists can block stress-induced reinstatement of drug-seeking have been done 
in rats and have been done using non-specific α2-AR agonists (Highfield et al., 
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2001; Wang et al., 2001; Leri et al., 2002). My project, however, focused on the 
α2A-AR-specific agonist guanfacine and exclusively involved studies done in 
mice. Therefore, I wanted to confirm that guanfacine could block stress-induced 
reinstatement of conditioned place preference in mice. For four days mice were 
conditioned to contextually pair one side of a two-sided chamber with cocaine. To 
do this, mice were daily given i.p. injections of cocaine and then allowed 30 
minutes on the cocaine-paired side of a double sided chamber. Alternately, mice 
underwent daily sessions in which they received i.p. injections of saline and were 
only allowed access to the opposite side of the chamber. After four days of 
conditioning, mice were then tested for place preference through a free 
exploration session in which we ensured that, given free access to both sides of 
the chamber, the mice spent significantly more time on the cocaine-paired side 
than the saline-paired side. After four days of free-exploration sessions, the 
preference for the cocaine-paired side of the chamber was extinguished. After 
extinction, we attempted to reinstate preference for the cocaine-paired side of the 
CPP chamber by two different conditions. Since we think that guanfacine should 
preferentially block stress-induced reinstatement, but not drug-priming induced 
reinstatement, we attempted to compare the effects of i.p. guanfacine on these 
two different methods of reinstatement of drug-seeking. In the stress-induced 
reinstatement we exposed the mice to forced-swim immediately before giving the 
mice free access to both sides of the CPP chamber. For drug-priming 
reinstatement we injected the mice with i.p. cocaine immediately before giving 
the mice free access to both sides of the chamber. In both the forced-swim and 
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drug-priming conditions, half the mice were injected with i.p. guanfacine and the 
other half were injected with i.p. saline 30 minutes before either of the 
reinstatement conditions. However, reinstatement was not successful in either 
the drug-priming or the stress conditions, so we could not tell if guanfacine was 
able to block specifically stress-induced reinstatement of drug-seeking in mice. 
The insular cortex input to the BNST and oEPSCs in Thy1-COP4 mice show 
possible off-target sensitivity to guanfacine 
 
                   
Figure 17. Decrease of excitatory transmission from the insular cortex 
input to the BNST is not blocked by pre-incubation with atipamezole. 
Experiments showing the decrease in excitatory transmission from the insular 
input to the BNST with guanfacine application done in normal ACSF are shown in 
gray circles. Experiments showing the decrease in excitatory transmission from 
the insular input to the BNST with guanfacine application after pre-incubation 
with atipamezole are shown in gray circles (37.9% ± 7.6%, t(3)=4.98, p<0.05, 
n=4). 
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Figure 18. Depression of excitatory transmission from the insular input to 
the BNST is not reversed by subsequent application of atipamezole. 
Guanfacine decreased the size of oEPSCs recorded from the insular cortex input 
to the BNST, but this depression was not reversed by subsequent atipamezole 
application (43.7% ± 7.5%, t(6)=5.82, p<0.01, n=7). 
 
  
 
 In addition to the PBN and the BLA, another input to the BNST whose 
sensitivity to guanfacine that I examined was the insular cortex. Application of 
guanfacine to oEPSCs recorded from the insular cortex input to the BNST 
showed a decrease in excitatory transmission, similar to the PBN input. However, 
unlike the PBN input, this depression was not reversed by subsequent 
application of atipamezole (37.9% ± 7.6%, t(3)=4.98, p<0.05, n=4) (Figure 17). 
Similarly, this decrease in excitatory transmission in the insular cortex input was 
not blocked by pre-incubation of slices with atipamezole (43.7% ± 7.5%, 
t(6)=5.82, p<0.01, n=7) (Figure 18). Therefore, it is possible that this decrease in 
excitatory transmission of the insular cortex input to the BNST may be due to off-
target, non-α2A-AR-dependent effects of guanfacine.  
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 Further evidence of a possible off-target action of guanfacine was 
observed in oEPSC recordings done in Thy1-COP4 mice. In oEPSC recordings 
done in Thy1-COP4 mice, oEPSCs were decreased by guanfacine, but this 
decrease was not reversed by subsequent application of atipamezole (Figure 19) 
(t(2,7)=15.7, p<0.01., n=8). Taken together, the inability of atipamezole to either 
reverse or block depression of oEPSCs from the insular cortex or in Thy1-COP4 
mice suggest that guanfacine may have off-target, non-specific effects that are 
able to decrease excitatory transmission in certain studies. Therefore, it will be 
important in future studies to either block or reverse observed effects of 
guanfacine with atipamezole to make sure that the effect that we are studying is 
α2A-AR-mediated and not this off-target effect. In future work it will also be 
important to figure out the receptor types that guanfacine is acting on to cause 
these off-target effects as these off-target effects may contribute to the 
decreased efficacy of guanfacine in preventing stress-induced relapse of drug-
seeking behavior in humans. 
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Figure 19. Decrease of excitatory transmission observed in voltage-clamp 
oEPSC recordings done in Thy1-COP4 mice with guanfacine application is 
not reversed by atipamezole. Guanfacine decreases the size of oEPSCs 
recorded from Thy1-COP4 mice and this decrease was not reversed by 
subsequent application of atipamezole (t(2,7)=15.7, p<0.01., n=8). 
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Initial pharmacological characterization of α2A-AR heteroreceptor knockout 
 
                                     
                          
Figure 20. Partial pharmacological characterization of the post-synaptic 
knock-out mouse. A) Guanfacine does not significantly decrease excitatory 
transmission in BNST whole cell recordings in α2A-AR postsynaptic KO mice. B) 
Guanfacine decreases excitatory transmission in the BNST of wild-type mice. C) 
Methoxamine does not significantly decrease excitatory field potential recordings 
done in α2A-AR postsynaptic KO mice. 
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 I hoped to be able to more specifically implicate α2A-AR heteroreceptors 
as being responsible for the decrease in excitatory transmission observed in the 
BNST with guanfacine application. I attempted to do this through the use of a 
transgenic “α2A-AR heteroreceptor KO” or “postsynaptic KO” mouse, in which α2A-
-ARs are knocked out of the mouse, but then the α2A-AR gene is overexpressed 
under the DBH promoter, which results in α2A-AR expression specifically on 
norepinephrine terminals. As a result, α2A-ARs are knocked out everywhere in 
the mouse except for on NE terminals, thus resulting in an effective 
“heteroreceptor KO” for α2A-AR with preservation of α2A-AR autoreceptors. When 
guanfacine was applied to whole cell electrical EPSC recordings done in 
postsynaptic KO mice depression of the EPSCs was not observed (t(5)=0.9, n.s., 
n=6), consistent with α2A-AR heteroreceptors being responsible for the 
guanfacine-mediated depression of excitatory transmission. As a control, 
depression of excitatory transmission by guanfacine was still observed in whole 
cell recordings done in wild-type mice (t(2)=4.3, p<0.05, n=3). However, I wanted 
to ensure that overall NE signaling was restored by expression of the α2A-AR on 
NE terminals in the transgenic mouse since we have observed previously that 
NE signaling is disrupted in complete α2A-AR KO mice (Egli et al., 2005). When I 
tried to apply the α1-AR methoxamine to field potential recordings I did not 
observe a significant decrease in excitatory transmission as we expected (t(5)=2, 
n.s., n=6) (McElligott and Winder, 2008). Therefore, further characterization is 
needed in these mice to ensure that α2A-ARs are indeed expressed on NE 
terminals projecting from the NTS to the BNST and that there is enough 
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autoreceptor expression of α2A-ARs in the postsynaptic KO mouse to keep NE 
signaling intact. 
 
 
The N1 of field potential recordings in wild type mice is decreased by 
guanfacine 
                                
 
Figure 21. The N1 deflection of field potential recordings done in wild-type 
mice is decreased by guanfacine. There is a significant decrease in the size of 
the N1 recorded from wild-type mice with guanfacine application.  
  
 
 
 Application of guanfacine to the N1 deflection of the electrical field 
potentials recorded in wild-type mice does show a significant decrease in size 
(t(4)=3.7, p<0.05, n=5). However, there does not appear to be a major drug effect 
observed in graphical analysis of the data (Figure 21). Therefore, this significant 
decrease in size of the N1 may be slight run down of the N1 during the course of 
the recordings. This decrease may also be due to the off-target effects of 
guanfacine described in Figure 18 and 19. The N1 is thought to be due to the 
presynaptic fiber volley caused by the electrical stimulation. Therefore, it is also 
possible that guanfacine is altering the excitability of the presynaptic cell such 
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that it is not as responsive to electrical stimulation. 
 
HCN1 channels in the BNST likely do not contribute to an increase 
postsynaptic excitability in response to guanfacine 	  
 It has been shown that post-synaptic α2A-ARs in the prefrontal cortex can 
increase post-synaptic excitability by closing HCN channels (Wang et al., 2007). 
Further, it has been shown that mRNA for HCN1 channels is expressed in BNST 
cells (Hammack et al., 2007). Therefore, it is possible that the increase in c-fos 
expression that we observe with i.p. guanfacine is due to signaling through 
activated postsynaptic α2A-ARs  leading to downstream closing of HCN1 
channels. In order to test this hypothesis, I made use of an HCN1 KO mouse 
line. The mice were handled for five days as described above and then injected 
with guanfacine (i.p., 1 mg/kg) ninety-minutes to two hours prior to transcardial 
perfusion. Slices were then prepared of the BNST and free-floated for 
immunohistochemical staining for c-fos with DAB. I hypothesized that if the 
closing of HCN1 channels by downstream signaling of activated α2A-ARs was 
responsible for the increase in c-fos expression in the BNST following i.p. 
guanfacine, we would see a dramatic reduction in the amount of c-fos staining in 
HCN1 KO mice. Instead, I saw comparable levels of c-fos staining in HCN1 KO 
mice as was seen in WT mice (data not shown). Therefore, we decided not to 
pursue HCN1 channels as a mechanism of increased c-fos expression any 
further.  
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